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SUMMARY  
 
 
Reproduction is regulated through the integration of information that comes 
from the hypothalamus, hypophysis, and the ovary. There are critical hormone 
sensitive periods during development during which they are especially vulnerable 
to exposure to abnormal hormonal levels resulting from metabolic problems or 
environmental sources. These exposures may permanently alter the 
differentiation and function of reproductive organs. Several studies performed in 
humans and animal models have suggested that polycystic ovary syndrome 
(PCOS) originates during early development due to exposure to abnormal 
steroidal hormone levels. Supporting this, our group recently reported that the 
administration of a single dose of estradiol valerate (EV) to newborn rats can 
irreversibly program the polycystic ovary condition during adulthood. However, 
there is no information about how this neonatal exposure to a single dose of EV 
can determine the functional and structural changes seen in the adult ovary. The 
aim of this research was to determine if there are genes—primarily those most 
reported to be related to PCOS in humans—with permanently altered expression 
and if these expression patterns are due to modifications in the methylation 
pattern in their DNA sequence. 
A single dose (10 mg/kg) of EV was administered to neonatal rats, and 
PCR array and real-time PCR analyses were conducted to examine the 
subsequent gene expression patterns of growth factors, nuclear receptors, and 
coregulators. Twenty-four hours after the exposure, the EV-exposed rat ovaries 
expressed more androgen receptor (Ar) than did the control ovaries; in the 60-
day old rats, the Ar mRNA levels decreased 6.4-fold relative to the controls. The 
interstitial tissue and antral follicles from the adult EV-treated rats expressed more 
Ar than did the control preantral follicles, suggesting a failure of the control 
mechanism for Ar expression in antral follicles. Using the mass-array technique, 
the methylation patterns of different transcription factor binding sites were found 
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to be associated with the Ar gene. NBRE, the response element of nerve growth 
factor-induced B (Ngfi-b), was hypomethylated in the Ar gene from the EV-treated 
ovaries. There was also an increase in anti-Müllerian hormone (AMH) expression 
in adult ovaries (mRNA and protein) that was induced by the neonatal exposure 
to estradiol. The EV-treated rat ovaries had a higher level of AMH 
immunoreactivity in the antral follicles than did the controls; however, no 
significant differences were seen between the preantral follicles of the treated and 
control groups. 
The methylation pattern of the Amh gene from the ovaries of EV-treated 
adult rats showed differential methylation in the CpGs related to the estradiol 
response element (ERE) in the Amh gene. The neonatal ovary samples had 
hypermethylated CpGs in comparison to the 30- and 60-day old rats; the samples 
(granulosa cells) from the 60-day old rats had more methylation of the CpGs than 
did those from the 30-day old rats; thus, the methylation pattern depended on the 
stage of development. When we compared the EV-exposed and control rats, we 
found more methylation of the CpGs in the samples from the 60-day old EV-
exposed rats than in those from the controls; there were no differences between 
the groups for the 2- and 30-day old rats. 
This work demonstrated that the neonatal exposure to estradiol induces an 
overexpression of AMH and AR in the rat ovary. The mechanism by which these 
changes are induced may involve an increase in the methylation of the ERE 
associated with the Amh gene, suggesting that the change in methylation allows 
ESR1 to induce Amh expression. The hypomethylation of NBRE associated with 
the AR gene suggests that AR expression may be induced in response to nerve 
growth factor or luteinizing hormone. These epigenetic modifications found in the 
current rat model provide a new framework for understanding the genesis of the 
polycystic ovary and its maintenance in humans, allowing more focus on the 
effects due to estrogen exposure. 
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DEUTSCHE ZUSAMMENFASSUNG 
 
Die Fortpflanzung in Säugetieren wird durch Signale aus dem 
Hypothalamus, der Hypophyse und der Gebärmutter gesteuert. Während der 
Anlage der Gebärmutter in der Embryonalentwicklung gibt es ein kritisches 
Zeitfenster bei dem die Entwicklung durch veränderte Hormonspiegel oder 
andere äußere Einflüsse gestört werden kann. Dabei kann es zur permanenten 
Schädigung der reproduktiven Organe kommen. Studien am Menschen und in 
Tiermodellen legen nahe, dass das sogenannte Polyzystische Ovarialsyndrom 
durch erhöhte Steroidhormonspiegel verursacht wird. So konnte unsere 
Arbeitsgruppe kürzlich zeigen, dass bei neugeborenen Ratten die Gabe einer 
einzigen Dosis Estradiolvalerat (EV) ausreicht um ein Polyzystisches 
Ovarialsyndrom in den erwachsenen Tieren zu erzeugen. Die zugrundeliegenden 
Mechanismen sind allerdings bis heute nicht bekannt. 
 
Ziel dieser Arbeit war es zu untersuchen, ob die Expression bestimmter 
Gene in erwachsenen Ratten durch die Estradiolvaleratgabe im neonatalen 
Stadium permanent verändert wird und ob die veränderte Genexpression mit 
epigenetischen Veränderungen auf der Ebene der DNA Methylierung einhergeht. 
  
Hierzu wurden neugeborene Ratten mit einer einzigen Dosis EV (10 
mg/Kg) behandelt um anschließend die Genexpression von Wachstumsfaktoren, 
nukleären Hormonrezeptoren und ihre Kofaktoren mittels PCR Arrays und 
quantitativer RT-PCR zu untersuchen. Wir konnten zeigen, dass die Ovarien von 
EV-behandelten Ratten das Androgenrezeptorgen (Ar) nach 24h stärker 
exprimierten als die Kontrollen. Nach 60 Tagen ging die ovariale Ar Expression 
allerdings um das 4-6-fache gegenüber unbehandelten Tieren zurück. 
Histologisch war die Ar Expression in antralen Follikeln und im Interstitium vom 
EV-behandelten adulten Tieren stärker als in preantralen Follikeln, was auf eine 
Störung von Regulationsmechanismen in antralen Follikeln hindeutet. Mittels 
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MassArray-Technologie konnte außerdem gezeigt werden, dass die veränderte 
Ar Expression in EV-behandelten Tieren mit der verringerten DNA Methylierung 
einer potentiellen Transkriptionsfaktorbindestelle (NBRE: nerve growth factor-
induced B response element) korreliert. Daneben war die Expression des Anti-
Müller-Hormons (AMH) in Ovarien von EV-behandelten adulten Tieren sowohl auf 
mRNA als auch auf Proteinebene erhöht. Immunhistologisch zeigten 
insbesondere die antralen Follikeln von EV-behandelten adulten Tieren (nicht 
aber Interstitium und preantrale Follikeln) eine stärkere Färbung für AMH. Auch 
im Amh Gen konnten entwicklungs- und behandlungsabhängige Veränderungen 
der DNA Methylierung gemessen werden. Eine Bindungsstelle für den 
Estrogenrezeptor (ERE: estradiol response element) im Amh Gen zeigte 
Methylierungsunterschiede in Ovarien von adulten EV-behandelten Ratten. In 
normalen Tieren war der Methylierungsstatus dieser Region abhängig vom 
Entwicklungsstadium: im Vergleich zu 30 und 60 Tage alten Ratten war das 
Element in neugeborenen Ratten hypermethyliert und in Granulosazellpräperaten 
von 30 Tage alten Ratten weniger methyliert als in Präparaten von 60 Tage alten 
Tieren. Im Vergleich mit EV-behandelten Tieren zeigten Proben von 60 Tage 
alten Tieren eine signifikant erhöhte DNA Methylierung, während EV-behandelte 
neugeborene und 30 Tage alte Tiere sich nicht signifikant von den Kontrollen 
unterschieden.  
 
In dieser Arbeit konnte also gezeigt werden, dass bei Ratten die Gabe von 
Estradiol im neonatalen Stadium zu einer ovarialen Überproduktion von AMH und 
AR führt. Die Mechanismen die zu diesen Veränderungen führen könnten mit dem 
Verlust der DNA Methylierung im ERE des Amh Gens zusammenhängen, was 
vermutlich zu einer erhöhten ESR1-Bindung und AMH Expression führt. Die 
Hypomethylierung des NBRE im Ar Gen deutet darauf hin, dass hier NGF (nerve 
growth factor) oder LH (luteinisierende Hormon) an der veränderten Regulation 
beteiligt sind.  
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Die im Rattenmodel gefundenen epigenetischen Veränderungen bieten 
neue Anhaltspunkte um die Entstehung und die Persistenz des Polyzystische 
Ovarialsyndroms im Menschen besser zu verstehen und zukünftige Forschung 
wird sich noch gründlicher mit den Effekten der Estrogenexposition 
auseinandersetzen müssen.  
 
 
1 
 
INTRODUCTION 
 
 
2.1. General antecedents 
 
Reproduction, a fundamental physiological function, is regulated through 
the integration of information that comes from the hypothalamus, hypophysis, and 
ovaries. The hypophysis responds to gonadotropin releasing hormone by 
secreting luteinizing hormone (LH) and follicle stimulating hormone (FSH), which 
in turn modulate the folliculogenesis and steroidogenesis in the ovary during the 
mammalian reproductive cycle. LH receptors are localized in theca, granulosa, 
and interstitial cells; FSH receptors are localized in the granulosa cells. FSH 
induces the synthesis of estrogens and the recruitment and growth of ovarian 
follicles, while LH induces ovulation and the formation of corpora lutea. The 
steroidal hormones produced by the ovary in response to gonadotropins can act 
on the hypothalamus and hypophysis, controlling the endocrine axis through 
positive and negative feedback (Genuth 2005). Parallel to the endocrine control 
of reproductive function, there is a complementary regulation through the 
hypothalamus-celiac ganglion-ovary axis. The primary neurotransmitter acting in 
the ovary is noradrenaline (NA), which is released from neuron terminals 
originating in the celiac ganglia and thecal layer of the ovarian follicles (Lawrence 
& Burden 1980).   
 
In mammals, ovarian folliculogenesis starts with the formation of primordial 
follicles, a process known as nest breakdown, which allows the oocytes to be 
surrounded by a layer of somatic cells, thus forming the primordial follicles in a 
process known as follicular assembly. In humans, this process occurs during the 
third trimester of gestation, whereas in rats it occurs neonatally, between 24 and 
72 hours after birth . Once follicular development begins, it continues throughout 
2 
 
postnatal life. During this time the oocyte enlarges while the granulosa and theca 
cells proliferate, increasing the layers of cells surrounding the oocyte. This 
proliferative phase ends as follicular fluid begins to accumulate and the antral 
cavity forms (Rajah et al. 1992, Leung & Adashi 2004, Pepling 2012), see Figure 
1. Each of the different steps of follicular development are under the control of 
different endocrine and paracrine factors (gonadotropins, growth factors, and 
steroidal hormones), making this process vulnerable to hormonal changes 
induced by external factors.  
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Figure 1. Schematic view of folliculogenesis.  
In mammals, ovarian folliculogenesis begins with the formation of primordial follicles, a 
process known as nest breakdown, where oocytes are surrounded by a single layer of 
flattened granulosa cells (GCs); this process occurs before (humans) or immediately after 
birth (rats). After puberty, a number of follicles start growing to ovulate in each estrus 
cycle throughout the female reproductive lifespan. Primordial follicles are activated to 
grow into primary follicles (with a single layer of cuboidal GCs) and subsequently into 
secondary follicles (with stratified GCs without an antrum). Theca cells begin to emerge 
and form a layer around the GC layer after the formation of secondary follicles. Antral 
follicles with mature theca cells and a vascular network within the thecal layer are then 
formed, and more developed antral follicles are finally ovulated. If the preovulatory follicle 
is not capable of ovulation, it may be transformed into a cystic structure, such as a type 
III follicle (large follicles devoid of oocytes containing four or five plicated layers of small, 
densely packed GCs surrounding a very large antrum) and display a seemingly normal 
thecal compartment, precystic or cystic follicle (follicles devoid of oocytes with a large 
antral cavity, an enlarged thecal cell layer, and most frequently, a thin monolayer), and 
GC compartment containing apparently healthy cells.(Hemmings et al. 1983, Brawer et 
al. 1989, Convery et al. 1990, Lara et al. 2000, Leung & Adashi 2004, Matsuda et al. 
2012) 
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 The growing incidence of infertility and reproductive disorders in humans 
and wildlife have alerted us to the influence that the increasing amounts of 
industrial waste and agricultural products with estrogenic activity that are 
produced and released into the environment have over reproductive function 
(Danzo 1998, DeRosa et al. 1998, Tyler et al. 1998, Diamanti-Kandarakis et al. 
2009, Patisaul & Adewale 2009). These molecules that mimic or block hormonal 
activity are known as endocrine disruptors (EDs). They are natural or synthetic 
molecules that can alter homeostasis and the hormonal system, if present, either 
by environmental exposure or inappropriate exposure during development 
(Diamanti-Kandarakis et al. 2009). EDs exert their action through different 
pathways that converge on the molecular targets of the endocrine and 
reproductive system such as hormone receptors, enzymatic pathways involved in 
biosynthesis, and/or steroid hormone metabolism. Exposure to EDs during the 
sensitivity period can alter the normal development of the ovary, causing 
alterations in morphological and follicular development and malfunctions during 
the adult period (Jefferson et al. 2006, Uzumcu et al. 2006, Sotomayor-Zarate et 
al. 2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012, Nilsson et al. 2012). 
These alterations in the rat ovary can be inherited by the next generation through 
changes in the pattern of DNA methylation, because cellular differentiation of the 
rat ovary begins around the time of birth. The germ cell re-methylation is initiated 
during the postnatal period and continues throughout the oocyte growth period 
until the preantral follicle stage (Hirshfield 1991, Rajah et al. 1992, Uzumcu et al. 
2006). Regardless of the source of hormones or EDs during this period, they 
would alter the normal development of the offspring due to a reprogramming of 
the genes. 
 
There are several pathological conditions in which the hormonal 
environment is altered during development, such as adrenal hyperplasia, obesity, 
and polycystic ovary syndrome (PCOS) (Rittmaster et al. 1993, Speiser 2001, 
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Maliqueo et al. 2013). PCOS is a complex endocrine disorder characterized by 
hyperandrogenism, ovulatory/menstrual irregularity, and polycystic ovaries, which 
affects 5–10% of women of reproductive age (Goodarzi et al. 2011). Women with 
PCOS exhibit a significant increase in androgen concentrations during pregnancy 
(Sir-Petermann et al. 2002). An important proportion of the first-degree female 
relatives of a women with PCOS have been shown to be at risk for developing 
PCOS (Kahsar-Miller et al. 2001). In fact, in comparison with control girls, 
prepubertal girls exhibit higher levels of anti-Müllerian hormone (AMH), a marker 
of growing follicles, beginning at the peripubertal stage (Sir-Petermann et al. 
2006, Crisosto et al. 2007). It has been proposed that this inheritance is not the 
result of a genetic condition, but is due to fetal programming (Goodarzi et al. 2011, 
Padmanabhan & Veiga-Lopez 2011). Supporting this, experimental treatment of 
PCOS gestating mothers with the insulin sensitizer drug metformin improved the 
altered endocrine-metabolic environment of the PCOS mothers and the AMH 
levels in their daughters, suggesting the follicular alterations described in adult 
PCOS women may appear early during development (Crisosto et al. 2012). This 
is supported by several studies in animal models that have demonstrated a 
relationship between programmed PCO morphology during adulthood and 
prenatal or neonatal exposure to endocrine-disrupting compounds such as 
estrogens or aromatizable androgens (Rosa-e-Silva et al. 2003, Abbott et al. 
2006, Crain et al. 2008, Sotomayor-Zarate et al. 2008, Padmanabhan et al. 2010). 
 
In comparison to ovarian development in humans, the rat is an immature 
mammal, not reaching the ovarian primary follicle population until shortly after 
birth, whereas humans reach this step of development during the third trimester 
of pregnancy (Kurilo 1981, Rajah et al. 1992). The neonatal rat is a good model 
for investigating whether a change in hormonal environment can permanently 
modify ovarian function and follicular development. Our group has previously 
demonstrated that the neonatal stage in rats is the temporal window of sensitivity 
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during which exposure to a single dose of estradiol induces irreversible damage 
to folliculogenesis, ovulation, and reproductive physiology, thereby establishing 
or programming the polycystic ovary condition of adults (Sotomayor-Zarate et al. 
2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012). See Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The morphological aspects of ovaries from 60-day old rats. 
Photomicrographs of ovarian histology from a control rat (A) or from an EV-exposed rat 
(B). Note that the control ovaries contain corpora lutea, a sign of ovulation, while the EV-
treated ovaries have follicular cysts. Bars = 500 µm. Image adapted from Sotomayor-
Zarate et al.(2008). 
 
2.2. Endocrine disruptors, epigenetics, and development. 
 
From a physiological perspective, an endocrine-disrupting substance is a 
natural or synthetic compound that, through environmental or inappropriate 
exposure during development, alters the hormonal and homeostatic systems that 
enable the organism to communicate with and respond to its environment 
(Diamanti-Kandarakis et al. 2009). If the exposure to these molecules occurs 
during the critical hormone-sensitive period, these substances can permanently 
alter the differentiation and function of reproductive organs (Barker 1998, 
Nathanielsz 1999, Rhind et al. 2001). Different studies have demonstrated that 
A B 
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ED exposure during the pre- and post-natal period has an adverse effect on the 
reproductive system, inducing permanent changes in the progeny, including 
transferring these changes transgenerationally via epigenetic changes (Li et al. 
1997, Crews & McLachlan 2006). These types of changes, comprised of DNA 
methylation and post-translational histone modifications, interact with regulatory 
proteins and non-coding RNA to reorganize the chromatin in active or inactive 
domains (euchromatin or heterochromatin) (Geneviève et al. 2009). The normal 
development of mammals requires the activity of DNA methyl transferase 
(DNMTs) to establish de novo methylation (DNMT3A and B) and maintain 
methylation (DNMT1) in the genome. The expression levels of these enzymes are 
highly regulated and peak during specific stages of postnatal development of the 
mammalian ovary (Schaefer et al. 2007, Zama & Uzumcu 2009).  
 
Because the cellular differentiation of the rat ovary begins around the time 
of birth, with germ cell re-methylation initiated during the postnatal period and 
continuing throughout the oocyte growth period until the preantral follicle stage 
(Hirshfield 1991, Rajah et al. 1992, Uzumcu et al. 2006), the effects of EDs on the 
ovary during the sensitivity window can be inherited by the next generation 
through changes in the DNA methylation pattern.(Zama & Uzumcu 2009) . An 
example of this is exposure to methoxychlor (MXC) during the embryonic-
neonatal period, which generates a hypermethylation of ovarian genes as adults 
and is associated with an increase in DNMT expression (Zama & Uzumcu 2009). 
Previous studies in our laboratory have demonstrated that the administration of a 
single dose of estradiol valerate (EV) to neonatal rats induces estrous acyclicity, 
in addition to the morphological alterations in the ovary that result in a polycystic-
ovary morphology in adulthood (Sotomayor-Zarate et al. 2008, Cruz et al. 2012). 
This suggests that the effects of the EV exerted during the neonatal period act to 
determine ovarian function during development. It also strongly suggests there 
may be epigenetic changes in the genes that are regulating ovarian morphology 
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and function. It would be of interest to identify the modified genes resulting from 
this early estradiol exposure and their pattern of expression during development.  
 
 
2.3. Polycystic ovary syndrome and its possible mechanisms. 
 
According to the Rotterdam criteria (2003), PCOS is a highly prevalent 
heterogeneous syndrome characterized by clinical and/or biochemical androgen 
excess, oligo- and/or anovulation, and polycystic ovaries (2004). Many 
experimental observations strongly suggest that PCOS is primarily the result of 
androgen excess, and it is associated with endocrine, metabolic, cardiovascular, 
reproductive, and psychological disorders (Goodarzi et al. 2011, Shannon & 
Wang 2012). In patients with PCOS, ovarian hyperandrogenism, 
hyperinsulinemia due to insulin resistance, and altered intraovarian paracrine 
signaling can disrupt follicle growth, in addition to menstrual irregularity, 
anovulatory subfertility and the accumulation of small antral follicles within the 
periphery of the ovary, resulting in a polycystic morphology (Goodarzi et al. 2011). 
Follicles from PCOS patients fail to mature even when they are exposed to normal 
serum FSH levels (reviewed in Sandera et al (2011). This failure of the PCOS 
follicles to respond to endogenous or exogenous gonadotropins and to mature 
suggests alterations in modulators within the ovary other than those involved in 
the classical gonadotropin pathway. Almost 70% of the observed variability in the 
pathogenesis of PCOS is attributed to polygenetic influences. These genes can 
be grouped in three main groups: genes involved in the biosynthesis and activity 
of androgens, genes that correlate with insulin resistance, and genes that encode 
for inflammatory cytokines (Deligeoroglou et al. 2009, Shannon & Wang 2012). 
Studies have shown that women with PCOS overexpress the follicle-stimulating 
hormone receptor (FSHR), AR, AMH, and the AMH receptor in granulosa cells 
(Sir-Petermann et al. 2006, Catteau-Jonard et al. 2008, Sir-Petermann et al. 
2012), suggesting a deregulation of granulosa cell function. It has also been 
9 
 
suggested that the increase in AR expression in PCOS patients may stimulate the 
development and survival of an excessive number of follicles while preventing 
their maturation by interfering with the release of gonadotropins, thus leading to 
the development of PCOS (Weil et al. 1998).  
 
Some studies have shown that infant, young, and adolescent daughters of 
women with PCOS exhibit higher levels of AMH in comparison to control girls (Sir-
Petermann et al. 2006, Crisosto et al. 2007, Sir-Petermann et al. 2012). The 
improved endocrine-metabolic environment of PCOS gestating mothers, and 
AMH levels in their daughters, in response to metformin treatment supports this 
(Crisosto et al. 2012). These results and studies of early hormone exposure and 
programming of reproductive function in various animal models suggest that the 
follicular alterations described in adult PCOS women may appear early during 
development(Franks et al. 2006, Dumesic et al. 2007, Sotomayor-Zarate et al. 
2008, Padmanabhan & Veiga-Lopez 2011, Cruz et al. 2012) 
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2.5. Rat as a model of the polycystic ovary. 
 
As mentioned previously, in comparison to humans the rat is an immature 
mammal with regard to ovarian development, reaching the ovarian primary follicle 
population shortly after birth, unlike humans, which do so during the third trimester 
of pregnancy (Kurilo 1981, Rajah et al. 1992). Thus, the neonatal rat is a good 
model for investigating whether changes in the hormonal environment can 
permanently modify ovarian function and follicular development. We previously 
reported that a single dose of EV injected into newborn rats established or 
programmed the polycystic-ovary condition of adulthood by inducing irreversible 
damage in folliculogenesis, ovulation, and reproductive physiology (Sotomayor-
Zarate et al. 2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012). Moreover, we 
demonstrated that the neonatal stage in rats is a temporal window of sensitivity to 
the estradiol effects: rats exposed to a single dose of estradiol at 1, 7, or 14 days 
postnatally had no estrous cycling activity and maintained a polycystic-ovary 
condition throughout the study (all rats were analyzed at 6-months old, i.e., at the 
beginning of the subfertility period). However, if the exposure to estradiol occurred 
after postnatal day 21, the induced PCO condition was reversible, demonstrating 
that estrogen-induced PCO is a transient condition when the exposure occurs 
after the critical period of development, but permanent when the estradiol 
exposure occurs during the neonatal-infantile period (Sotomayor-Zarate et al. 
2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012),  
 
That these effects could be induced by a single administration of the steroid 
during a specific window of postnatal development evokes the concept of 
“programming”, which is defined in the physiological context as an early stimulus 
or insult during a critical hormone-sensitive period that results in permanent 
effects during adulthood (Lucas 1991). Thus, the model of neonatal rat exposure 
to estradiol could be useful for studying what happens during the corresponding 
fetal period in humans (Rajah et al. 1992). 
11 
 
 
In summary: 
 
 Folliculogenesis is a process that can be altered by exposure to estradiol 
during the sensitivity window.  
 Many data suggest that the PCO is a programmed condition during the 
gestational period. 
 Animal models have shown that a single dose of estradiol may program 
the onset of PCO by an unknown mechanism that probably involves 
epigenetic modifications given the maintenance of the phenotype long after 
the exposure. 
 PCOS patients and their daughters have increased levels of AMH and AR 
expression, which has been related to the anovulation and folliculogenesis 
failure found in PCOS patients. 
With these antecedents, we postulate the following working hypothesis: 
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HYPOTHESIS 
 
 
“Neonatal exposure to estradiol induces epigenetic changes to anti-Müllerian 
hormone and androgen receptors that affect ovarian follicular development, which 
determines the polycystic ovary morphology” 
 
 
AIMS 
 
 
4.1. General aim. 
 
To determine if the neonatal exposure to estradiol valerate induces alterations in 
ovarian gene expression—specifically AMH and AR—and if there are epigenetic 
changes that can be related to that expression pattern.  
 
4.2. Specific aims: 
 
1) To determine if there are changes in genes related to the function and signaling 
of nuclear receptors and coregulators in neonatal rat ovaries 24 hours post-
exposure to EV and to determine if there are changes in genes related to growth 
factor function and signaling in 60-day old rats.  
 
2) To determine specifically which ovarian cell types have altered AR and AMH 
expression in 2-, 30-, and 60-day old rats exposed to EV during the neonatal 
period. 
 
3) To determine if Ar and Amh have epigenetic changes in the ovaries of EV-
exposed rats.  
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METHODS 
 
 
5.1. Animals and experimental design.  
 
Neonatal Sprague-Dawley rats derived from a stock maintained at the 
Faculty of Chemistry and Pharmaceutical Sciences from the University of Chile 
were used in this study. A single dose of EV (Sigma, St. Louis, MO, USA) was 
administrated during the first 12 hours after birth (n = 18). The administered dose 
was 10 mg/kg of body weight dissolved in 50 µL of sesame oil as the vehicle 
(Sigma, St. Louis, MO, USA) as previously described (Sotomayor-Zarate et al. 
2008). Controls were injected with the same volume of the vehicle (n = 18). As 
adults, the estrous cycling activity was also monitored by analysis of vaginal 
lavages taken at 10 AM daily to verify the stage of the estrous cycle, 
The rats were euthanized by decapitation 24 hours after the EV 
administration (2-day old rats) and at 30 or 60 days of age (n = 6 for EV-treated 
and control rats per age group). The ovaries were obtained and stored at -80°C 
(left ovary) or fixed in Bouin solution (right ovary). The left ovaries were used for 
RNA extractions or protein purifications. Because there is little RNA that can be 
obtained from a neonatal ovary, RNA was extracted from a pool of two ovaries. 
Blood plasma was collected for hormone determinations. 
All experimental procedures were approved by the Bioethics Committee of 
the Faculty of Chemistry and Pharmaceutical Sciences at the University of Chile 
and complied with national guidelines (CONICYT Guide for the Care and Use of 
Laboratory Animals). All efforts were made to minimize the number of animals 
used and their suffering. 
 
 
14 
 
5.2. Protein purification. 
 
The ovaries from 60-day old rats were homogenized with a glass 
homogenizer on ice in lysis buffer (50 mM Tris HCl; 150 mM NaCl; 0.1 mM EGTA; 
0.1 mM EDTA; 1% Triton X100; a protease inhibitor cocktail containing 2 mM 4-
(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), 0.3 μM aprotinin, 130 μM 
bestatin, 1 mM EDTA, 14 µM E-64, and 1 µM leupeptin (Sigma); 0.51 mM PMSF; 
and 1 mM DTT). The homogenized fraction was recovered and centrifuged at 
16,750 × g for 10 minutes at 4°C, and the recovered supernatant was stored at -
80°C until subsequent use. The extracted proteins were quantified by the Bradford 
method (Bradford 1976). 
 
5.3. Western blot 
 
Proteins (50 µg per lane) were resolved by SDS-PAGE (4% stacking gel, 
8% resolutive gel) and electrotransferred to a 0.2 µm-pore nitrocellulose 
membrane for 1 hour at 400 mA. Nonspecific binding sites were blocked by 
incubating the membranes with 5% non-fat milk diluted in T-TBS (0.1% Tween-
20 in Tris-buffered saline; TBS: 20 mM Tris, 137 mM NaCl, pH 7.6) for 1 hour at 
room temperature (RT) before incubating overnight (ON) at 4°C with rabbit anti-
androgen receptor (anti-AR; cat. no. ab74272; Abcam Ltd., Cambridge, UK) 
diluted 1:300 in T-TBS or with rabbit anti-β-tubulin antibody (cat. no. ab6046; 
Abcam Ltd., Cambridge, UK) diluted 1:10,000 in T-TBS. The membranes were 
then washed with T-TBS three times and incubated with a horseradish 
peroxidase-conjugated secondary antibody (goat anti-rabbit IgG) diluted 1:10,000 
in T-TBS for 1 hour at RT. The membranes were incubated with an enhanced 
chemiluminescent (ECL) western blotting substrate (Pierce, Rockford, IL, USA); 
images were obtained with photographic films and analyzed with the Genetools 
program (Syngene, Cambridge, UK). 
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.5.4. PCRarray 
 
To analyze the general modifications in gene expression, a quantitative 
RT-PCR-based array assay (PCR array) was performed containing 84 genes. To 
analyze The short term effects of EV on gene expression (2-day old rat ovaries) 
were analyzed with a PCR-array kit for nuclear receptors and coregulators 
(SABiosciences, Frederick, MD, USA) as described by the manufacturer 
instructions. For the long term effects, a PCR-array kit for growth factors 
(SABiosciences) was used with ovaries from 60-days old rats per the 
manufacturer instructions. 
Total RNA extractions from the ovaries of 2-, 30-, and 60-day old rats were 
performed using RNeasy columns (Qiagen, Hilden, Germany) as described by 
the manufacturer, which included digestion of the DNA by DNAse in the column. 
The integrity of the RNA was checked with denaturing agarose gel 
electrophoresis. 
The RNA (1 µL per sample) was quantified using a Nanodrop instrument 
(Thermos, Rockford, USA), and all of the samples had a 260/280 absorbance 
ratio over 1.8. Complementary DNA (cDNA) was synthesized using the RT2First 
Strand kit (SABiosciences). The cDNA from 2-day old rat ovaries was synthesized 
from 1 µg of pooled total RNA from 6 different ovaries. 
The PCR array protocol was performed using an IQ5 real-time 
thermocycler (BioRad) using the configuration provided by SABioscience for each 
set of plates. The threshold cycle (Ct) results were uploaded into a virtual platform 
from SABioscience for the analysis. Fold-change [2^(- Delta Delta Ct)] was 
represented by the normalized gene expression [2^(- Delta Ct)] in the EV-treated 
sample divided by the normalized gene expression [2^(- Delta Ct)] in the control 
sample. Fold-regulation represents the fold-change results in a biologically 
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meaningful way. A fold-change value greater than one indicated an increase or 
upregulation, and the fold-regulation was equal to the fold-change. A fold-change 
value less than one indicated a decrease or downregulation, and the fold-
regulation was the negative inverse of the fold-change. The formulas used for the 
analysis were as follows: 
∆Ct (treated) = Ct (Target “A”‐treated) – Ct (Ref “B”‐treated) 
∆Ct (control) = Ct (Target “A”‐control) – Ct (Ref “B”‐control) 
∆∆Ct = ∆Ct (treated) – ∆Ct (control) 
Normalized target gene expression level = 2(‐∆∆Ct) 
It was considered a cut-off when the determined mRNA was upregulated 
or downregulated at least 2-fold in comparison to the control value. 
 
 
5.5. Real time PCR 
 
After determining which genes were up- or downregulated, real-time PCR 
was performed using individual ovary samples. Primers were designed with the 
Primer Select program (DNASTAR Inc., USA) using the mRNA sequence 
provided by the PubMed database as the template. The primer designs were 
evaluated in silico using Primer-BLAST from PubMed 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to determine if there were 
amplification byproducts in the rat genome. The sequences from the designed 
and synthesized primers are shown in Table 1. 
The PCR reaction mix contained 10 µL of Brilliant II SYBR Green QPCR 
Master Mix (Agilent Technologies, Inc., California, USA); 0.25 µM of each 18S 
primer, 0.15 µM of each AMH primer, or 0.1 µM of each AR primer; 2 µL of cDNA; 
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and sterile water for a final volume of 20 µL. PCR reactions were performed on 
the IQ5 real-time thermocycler (BioRad) with the following conditions: 95°C for 5 
min for 1 cycle; 40 cycles at 95°C for 15 s, 60°C (AR and 18S) or 65C (AMH) for 
15 s, and 72°C for 30 s; 72°C for 7 min; and ending with a  4°C maintenance 
cycle. 
.  
18 
 
Table 1. Sequence of the primers designed for real-time PCR. 
The GenBank accession number of each gene used as a reference for the primer designs 
is indicated in parentheses. bp, base pair; fwd, forward primer; rev, reverse primer. 
.  
Gene  Primer Sequence Product 
Lenght  
AMH (NM_012902.1) fwd 5’-GGCTCGCCCTAACCCTTCAACC-3’ 312 bp 
rev 5’- GTCCCCGCAGAGCACGAACC-3’ 
AR (NM_012502.1) fwd 5'-AATGGGACCTTGGATGGAGAACTA-3' 297 bp 
rev 5'-TCATAACATTTCCGGAGACGACAC-3' 
ERα (NM_012689.1) fwd 5'-TCCTGGACAAGATCAACGACACT-3' 139 bp 
rev 5'-TGCTCCATGCCTTTGTTACTCA-3' 
ERβ (NM_012754.1) fwd 5'-GCAAACCAGGAGGCAGAAAGTAG-3' 154 bp 
rev 5'-GCCTGACGTGAGAAAGAAGCATC-3' 
Esrrg (NM_203336.1) fwd 5'-CCTGTCCGGAAACTGTATGATGA-3' 135 bp 
rev 5'-ATAGTGATACCCAGAGGCGATGTC-3' 
Ncoa3 (XM_215947.5) fwd 5'-GCCTACCTTGCCACTTCGTTCTAA-3' 181 bp 
rev 5-'CACTGCTGGGCTATAGGGACTGAC-3' 
TGF-α (NM_012671) fwd 5’-ACTCTGGGTACGTGGGTGTTCG-3’ 394 bp 
rev 5’-GGTTGTACATTGAGGGGGAAGGTC-3’ 
18S (NR_046237.1) fwd 5'-TCAAGAACGAAAGTCGGAGG-3' 489 bp 
rev 5'-GGACATCTAAGGGCATCACA-3' 
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5.6. Measurements of serum levels of estradiol. 
 
Serum levels of estradiol from 2-, 15-, 30-, and 60-day old rats were 
measured using the ELISA kit 11-ESTHU-E01 (ALPCO Diagnostics, Salem, NH, 
USA). The kit sensitivity was 10 pg/mL with a cross reactivity of less than 1.6% 
with other steroidal hormones. The intra- and interassay variability was less than 
10%. 
 
 
5.7. Immunohistochemistry. 
 
Immunohistochemistry (IHC) was performed on 6-µm slices from fixed and 
paraffin-embedded ovaries from 2- and 60-day old rats as previously described 
(Greiner et al. 2008) with rabbit anti-AR (cat. no. ab74272; Abcam Ltd., 
Cambridge, UK) diluted 1:100 or goat anti-AMH (cat. no. sc-6886; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) diluted 1:500. Biotinylated goat anti-rabbit 
IgG (cat. no. sc-2040; Santa Cruz Biotechnology) and biotinylated anti-Goat IgG 
(cat. no. BA-5000; Vector Laboratories, Inc. Burlingame, CA, USA) were used as 
secondary antibodies for AR and AMH, respectively. After incubating the samples 
with horseradish peroxidase streptavidin (cat. no. SA-5004; Vector Laboratories, 
Inc.), the ImmPACT VIP Peroxidase Substrate kit (Vector Laboratories, Inc.) was 
used to develop the samples following the manufacturer instructions. Images 
were obtained using an Olympus optical microscope (Olympus CX31, Tokyo, 
Japan) with Micrometrics SE Premium 4 software (ACCU-SCOPE, Inc., 
Commack, NY, USA). 
The results were analyzed by measuring the pixel intensities using the 
semiquantification tool IOD (Integrated Optical Density) of the Image Pro Plus 6.0 
program. Similar sections of at least 4 slices per ovary were analyzed. The relative 
contribution of AMH or AR to the total IOD (100%) of the whole ovary slice in the 
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image was calculated for each follicle, differentiating between preantral follicles, 
antral follicles, and corpora lutea. The results were expressed as the mean ± the 
standard error of the mean (SEM; n = 3 independent ovaries per group, 4 slices 
per ovary). 
 
 
5.8. Mass spectrometry analysis of bisulfite-converted DNA 
 
 
5.8.1. Principle of MassArray spectrometry  
 
EpiTYPER (Sequenom, San Diego, USA) is a tool used for detecting and 
quantifying methylated DNA based on bisulfite conversion. When genomic DNA 
is treated with bisulfite, the unmethylated cytosine residues are deaminated to 
uracil and transformed into thymidine during PCR amplification, whereas the 
methylated cytosine residues still appear as cytosines. Consequently, bisulfite 
treatment results in methylation dependent sequence conversions of C to T after 
PCR amplification. After amplification, the products are then treated with shrimp 
alkaline phosphatase (SAP) to dephosphorylate the unincorporated dNTPs from 
the PCR reaction. Subsequently, in vitro transcription is performed followed by 
RNase A specific cleavage to produce smaller fragments. The cleavage products 
are then prepared for analysis in the mass spectrometer. MALDI-TOF MS (matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry) detects the 
16 Da mass difference between the guanine and adenine residues (resulting from 
the C/T variations of the opposite strand) as a result of the methylated and 
unmethylated DNA templates. The MALDI-TOF MS data are then processed 
using the EpiTYPER software, which generates quantitative results for each 
cleavage product (Ehrich et al. 2005)  
 
21 
 
5.8.2. MassArray Protocol. 
 
To analyze the methylation pattern between ovarian compartments in 30- 
and 60-day old rats (EV-treated and controls), a protocol was used as described 
by Greiner et al. (2008) to separate the granulosa cells (GCs) from the residual 
ovary (RO), which principally contains theca and stromal cells. Briefly, the ovaries 
were punched with a needle and the GCs were gently squeezed out. The cells 
were suspended in 1 mL of PBS, centrifuged at 3600 × g for 5 min, and the 
supernatant was discarded. The GC pellets and ROs were frozen at -80°C until 
later use. Because the neonatal ovary is small and there are no granulosa cells 
due to there being no assembled follicles, the MassArray protocol for the ovaries 
from 2-day old rats was performed on complete ovaries. 
The DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) was used to 
purify genomic DNA from the GCs and ROs from the 30- and 60-day old rats and 
from the whole ovary from the 2-day old rats (n = 3 for each group) following the 
manufacturer instructions. 
 
The bisulfite conversion of genomic DNA was performed with the EZ DNA 
Methylation kit (Zymo Research, Orange, CA, USA) as described by the 
manufacturer with slight modifications as recommended in the EpiTYPER 
application guide from Sequenom. The oligonucleotides for amplifying the regions 
of interest were designed using the EpiDesigner web tool 
(http://www.epidesigner.com/) and the R program version 2.15.2 (The R 
Foundation for Statistical Computing, Vienna, Austria). The antisense primer was 
tagged with a T7-promoter sequence and a short eight base pair (bp) spacer 
sequence, while the sense primer had a 10-mer tag to balance the primer lengths. 
Sixteen amplicons for bisulfate conversion were designed using the genomic 
regulatory regions from AMH and AR (see Table 2 and Table 3 for sequence 
details) Figure 4 and Figure 5 show the regions covered by the primers for AMH 
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and AR, respectively. The genomic sequences were obtained from the University 
of California Santa Cruz (UCSC) Genome Browser 
(http://www.genome.ucsc.edu/), and the primers were synthesized by Sigma-
Aldrich (Deisenhofen, Germany). 
The PCR reactions, SAP treatment, in vitro transcription, RNase cleavage, 
and MALDI-TOF MS analysis were performed as described in the Sequenom 
protocols found in Ehrich et al. (2005) and Schmidl et al. (2009). Briefly, the 
regions of interest were amplified by PCR with a reverse primer harboring a T7-
polymerase promoter for in vitro transcription. After inactivating the 
unincorporated deoxynucleotide triphosphates by dephosphorylation with SAP, 
the amplicons were transcribed in vitro into RNA with T7-RNA polymerase. “T”-
specific cleavage was achieved with RNase A and modified cytosine triphosphate 
nucleotides to avoid “C” cleavage. The reactions were diluted with water and 
desalted with 6 mg of cation exchange resin (Sequenom, San Diego CA, USA). 
Finally, the reactions were spotted on a SpectroCHIP array with the Phusio chip 
module and measured with the MassARRAY Compact System (all Sequenom) 
[from the diploma thesis of Chistian Schmidl (2008)]. The raw data were then 
processed using the EpiTYPER version 1.0 software (Sequenom, San Diego, CA, 
USA).Figure 3 summarizes the protocol.  
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Figure 3. Schematic outline of the MassArray process. 
Genomic bisulfate-treated DNA is amplified by using primers located outside of the CpG 
islands, with one primer tagged with a T7-promoter sequence. The PCR product is 
transcribed into an RNA transcript and cleaved base specifically (note the figure shows 
U-specific cleavage, but the assay for this work used T-specific cleavage). The cleavage 
products are analyzed by MALDI-TOF mass spectrometry to obtain a characteristic mass 
signal pattern. In the case shown here, the PCR product is transcribed from the reverse 
strand and cleaved U-specifically. A methylated template (indicated in yellow) carries a 
conserved cytosine, and thus the reverse transcript of the PCR product contains CG 
sequences. For an unmethylated template (indicated in red), the cytosine is converted to 
uracil. As a result, the reverse transcript of the PCR product contains adenosines in those 
respective positions. The sequence changes from G to A yield 16-Da mass shifts. 
Cleavage product 1 has two methylation sites, and the mass signals of the cleavage 
product will differ by 32 Da when both CpG sites are either methylated or unmethylated. 
For cleavage products 2 and 3, mass shifts of 16 Da will be observed, because each 
contains only one methylation site. The spectrum can be analyzed for the 
presence/absence of mass signals to determine which CpGs in the template sequence 
are methylated, and the ratio of the peak areas of the corresponding mass signals can 
be used to estimate the relative methylation (taken from Ehrich et al. (2005)).   
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Table 2. MassArray primer for the anti-Müllerian hormone sequence. 
The genomic region covered by the primer pairs as indicated by the UCSC browser annotation is shown. The primers were 
designed to incorporate the T7 promoter sequence and a short eight base pair spacer sequence in the antisense primer, while 
the forward primer has a 10-mer tag to balance the primer lengths (shown in lower case). RC, reverse complement. 
 
 
 
Primer pair ID Sequence UCSC annotation 
AMH_promoter_2 Fwd 5'-aggaagagagAAGATGGGGTTTGGTTTTTTAGTAG-3' >chr7:11944336-11945793 (RC) 
 Rev 5'-cagtaatacgactcactatagggagaaggctCCACAAAATATATCCCACAAAATTC-3'  
AMH_promotor_3 Fwd 5'-aggaagagagGGTATAAAGGTTTAGGGGGATTGTT-3' >chr7:11944959-11945569 
 Rev 5'-cagtaatacgactcactatagggagaaggctCCCCCATATCTCCCTATCTACAATA-3'  
AMH_promotor_4 Fwd 5'-aggaagagagTTTTGTATGGTGGTATGGTAGGGT-3' >chr7:11945161-11945594 
 Rev 5'-cagtaatacgactcactatagggagaaggctCAAATAAACTCCCCAAACAAATAAA-3'  
AMH_STAT3_1 Fwd 5'-aggaagagagAGGAGGGAGGAGAAGTTTTAGGTTA-3' >chr7:11941350-11942146 
 Rev 5'-cagtaatacgactcactatagggagaaggctCAAAAAACACAAACAAAATCAATCA-3'  
AMH_GATA_1 Fwd 5'-aggaagagagGTAGGAGGTGTTGGATTGGTTTAG-3' >chr7:11956087-11956724 (RC) 
 Rev 5'-cagtaatacgactcactatagggagaaggctAACAACAAACAAATTCCAAAAAAAA-3'  
AMH_ERE_3 Fwd 5'-aggaagagagTTTATTTTTTTTGTTTGGTTGAAGG-3' >chr7:11943898-11944805 
 Rev 5'-cagtaatacgactcactatagggagaaggctAACCTCAAAAACTCAACTATCACCA-3' 
AMH_ERE_5 Fwd 5'-aggaagagagAGATGGTTAAGGGGTAAGGATAGTG-3' >chr7:11947268-11948031 (RC) 
 Rev 5'-cagtaatacgactcactatagggagaaggctCCCTCCTTCTTCTAAAAATTACCAA-3' 
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Figure 4. Schematic view of the anti-Müllerian hormone genomic region analyzed by MassArray.  
Primers were designed to amplify transcription factor binding sites or the promoter region. The amplicons for each primer pair 
are shown. Bottom: an amplified view of the region covered by the primers and the number of CpGs contained in each 
sequence (shown as lollipops). Black boxes, amplicon region; blue boxes, exons; blue line, introns. Note that the transcription 
of anti-Müllerian hormone starts from right to left in the scheme. ERE, estradiol response element. 
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Table 3. MassArray primers for the androgen receptor sequence. 
The genomic region covered by the primer pairs as indicated by the UCSC browser annotation is shown. The primers were 
designed to incorporate the T7 promoter sequence and a short eight base pair spacer sequence in the antisense primer, while 
the forward primer has a 10-mer tag to balance the primer lengths (shown in lower case). RC, reverse complement. 
Primer pair ID  Sequence UCSC annotation 
AR_ERE1 fwd 5'-aggaagagagTAGAAATGATTATTGGTTTTTTGGG-3' chrX:68532525-68533574 
 rev 5'-cagtaatacgactcactatagggagaaggctACTCCTCAAAAAATTAACACAAACC-3' 
AR_ERE_2 fwd 5'-aggaagagagTGTTGGAGGTATAGTATATGAGGTTTGA-3' >chrX:68682918-68684375 
 rev 5'-cagtaatacgactcactatagggagaaggctAAAAAAACATACCTCCCAAAATCCT-3' 
AR_ERE_3 fwd 5'-aggaagagagTTGTTGGAGGTATAGTATATGAGGTTTG-3' >chrX:68682918-68684375 
 rev 5'-cagtaatacgactcactatagggagaaggctACCTTTCAATCCACATTAAAAAAAT-3' 
AR_foxoA3_1 fwd 5'-aggaagagagAGGGTTTATTAGGATAAGTAGAAGGGAG-3' chrX:68531846-68533210 (RC) 
 rev 5'-cagtaatacgactcactatagggagaaggctCAACCCTCTATAATTTCTCTACCCAA-3' 
AR_promotor_1 fwd 5'-aggaagagagAAGTTAAAGTTTTTGTTTTGGAGTTT-3' >chrX:68533298-68533804 
 rev 5'-cagtaatacgactcactatagggagaaggctACTCAATCTTTTCCCCTCTAATACC-3' 
AR_NBRE_1 fwd 5'-aggaagagagAAGAGATTTGAGGTTTTAGGGAGTG-3' >chrX:68497617-68500594 (RC) 
 rev 5'-cagtaatacgactcactatagggagaaggctAAAACCTCTATACACCAAAATTCCA-3' 
AR_promotor_4 fwd 5'-aggaagagagGTGTAAATTGGTTGGTAGAGTTGGT-3' >chrX:68533162-68534096 (RC) 
 rev 5'-cagtaatacgactcactatagggagaaggctCCACTCCAATACCATACAAAAACTT-3' 
AR_NFKB_3 fwd 5'-aggaagagagAGTAAGGGAGGTTATTGGGGTTT-3' >chrX:68535239-68535629 
 rev 5'-cagtaatacgactcactatagggagaaggctCAACAATCTCTTCAATACCTTTACCC-3' 
AR_STAT3_1 fwd 5'-aggaagagagGAGTTTGTTGTTTATTGGAAGGGA-3' >chrX:68534079-68534830 
 rev 5'-cagtaatacgactcactatagggagaaggctCCCAAATAACCTCAAAATCTCCTAT-3' 
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Figure 5. Schematic view of the androgen receptor genomic region analyzed by MassArray. 
Primers were designed to amplify transcription factor binding sites or the promoter region. The amplicons for each primer pair 
are shown. Bottom: an amplified view of the region covered by the primers and the number of CpGs contained in each 
sequence (shown as lollipops). Black boxes, amplicon region; blue boxes, exons; blue line, introns. ERE, estradiol response 
element; NBRE, response element of the nerve growth factor-induced B. 
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5.9. Methyl-CpG immunoprecipitation. 
 
Methyl-CpG immunoprecipitation (MCIp) allows for the rapid enrichment of 
CpG-methylated DNA. The DNA was bound to the methyl-CpG binding domain 
(MBD) of human MBD2 (GenBank accession no. NM_003927; AA 144230) fused 
to the Fc tail of human IgG1 to form the MBD2-Fc fusion protein as previously 
described (Gebhard et al. 2006). The affinity to DNA increases with the density of 
methylated CpGs and is reduced with higher salt concentrations in the buffer, 
which allows for the enrichment of the methylated DNA on a matrix-protein 
complex with increased NaCl concentration in the wash buffer and collection of 
the flow-through recovering the less-methylated DNA. 
 
For the global methylation analyses, MCIp was performed with slight 
modifications (Schilling & Rehli 2007) using the EpiMark Methylated DNA 
Enrichment kit (New England BioLabs, Frankfurt, Germany) following the 
manufacturer protocol. In brief, the genomic DNA (500 ng per sample) from the 
GCs or RO was sonicated to a mean fragment size of 200 bp using a Covaris 
S220 sonifier (Covaris, Woburn, MA, USA) for 180 seconds with a 10% duty cycle, 
intensity of 5, and 200 cycles per burst. The fragment range was controlled by 
agarose-gel electrophoresis. The sonicated samples were incubated with 10 μL 
of Protein A Magnetic Beads coated with purified MBD-Fc protein in a buffer 
containing 150 mM NaCl for 1 hour at RT with rotation. The beads were washed 
with the working buffer to discard the unbound DNA fragments. The captured 
methylated CpG DNA was recovered from the magnetic beads by incubating them 
in DNAse-free water at 65°C for 15 min with frequent mixing and collecting the 
supernatant after centrifugation. The samples were desalted using the MinElute 
PCR Purification kit (Qiagen, Hilden, Germany). The separation of the CpG 
methylation densities of the individual MCIp fractions was controlled by real-time 
PCR using primers covering the imprinted PEG3 gene, which has a highly 
 29 
 
methylated-CpG content, and a region without any CpGs (empty_rat1) (see Table 
4). The recovered samples were prepared for sequencing using the Illumina 
Library Prep, Bioo NEXTflex (Bioo Scientific, Austin, Texas, USA) per the 
manufacturer instructions. Next-generation sequencing was performed by the 
Kompetenzzentrum für fluoreszente Bioanatytik (KFB; Regensburg, Germany). 
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Table 4. Primers used for methyl-CpG immunoprecipitation control. 
The genomic region covered by the primer pair as indicated by the UCSC browser 
annotation is shown. PEG3, paternally expressed gene 3, was used as a positive control 
of methylation; empty, genomic region without any CpGs was used as a negative control 
of methylation. 
 
 
 
 
 
5.10.1. RNA sequencing or whole genome expression analysis. 
 
 
To determine the expression patterns of the ovarian compartments in 60-
day old rats, we performed RNA sequencing (RNA-seq), which is a powerful tool 
for discovering, annotating, and quantifying RNA transcripts. Briefly, RNA is 
isolated from the cells, fragmented at random positions, and transcribed into 
cDNA. Fragments meeting specific size specifications (e.g., 200–300 bases) are 
retained for amplification using PCR. After amplification, the cDNA is sequenced 
using next-generation sequencing; the resulting reads are aligned to a reference 
genome, and the number of sequencing reads mapped to each gene in the 
reference is tabulated (Auer & Doerge 2010). 
 
Total RNA from the GCs and RO from 60-day old rats was isolated using 
the RNeasy Mini Kit (Qiagen, Hilden, Germany) using a pool of GCs or RO from 
3 different animals for each group. The RNA concentration and quality was 
Primer ID Sequence UCSC annotation 
rat_peg3 Fwd 5'-GTAGAGGCGAACCACCCAGAATCC-3' >chr1:71603939+71604028 
 Rev 5'-AGGACTCCTGCATCATCTGCGT-3'  
empty_rat1 Fwd 5'-GGTATGCCCAGAACTGAAAGCAAGGA-3' >chr4:228324268+228324351 
 Rev 5'-CTTTGAAACCCTTCTTTCACTGAATGCC-3'  
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assayed using an Agilent Bioanalyzer (Agilent Technologies, Inc., Santa Clara, 
California, USA). The Ribo-Zero Magnetic kit (Illumina; San Diego, USA) was 
used to remove the cytoplasmic (nuclear encoded) rRNA from the intact and 
degraded total RNA samples, which could interfere in the subsequent sequencing 
steps. The samples (~5.5 ng) were prepared for sequencing using the Script-Seq 
Complete kit (Illumina). 
 
 
5.10.2. Sequencing data analysis. 
 
 
Sequence tags were mapped to the current rat reference sequence (RGSC 
5.0/rn5)(Gibbs et al. 2004, Havlak et al. 2004) using the bioinformatic tool Tophat 
that aligns RNA-Seq reads to mammalian-sized genomes using the ultrahigh-
throughput short-read aligner Bowtie; this tool was also used to identify the splice 
junctions between the exons in the sequences (Trapnell et al. 2009). The 
bioinformatics tool EdgeR (Robinson et al. 2010) was used to assemble the 
transcripts, estimate their abundances, and test for differential expression and 
regulation in the RNA-Seq samples. The mapped RNA-seq and motif analyses 
were performed using HOMER (Hypergeometric Optimization of Motif 
EnRichment) as previously described (Heinz et al. 2010). ). Motif enrichment was 
done by comparing the sequences of the EV-treated GCs or RO (±100 bp for 
transcription factors) from 60-day old rats and their respective controls. Motif 
enrichment was calculated using the cumulative hypergeometric distribution of the 
total number of target and background sequence regions containing at least one 
instance of the motif. The motifs with the lowest hypergeometric q-value, which 
summarizes the false discovery rate estimation, were considered the top motifs. 
The use of this q-value controls for the error rate among a set of tests such as 
those obtained from the RNA-seq data analysis (Noble 2009). A gene ontology 
analysis was performed using the PANTHER (Protein Analysis Through 
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Evolutionary Relationships) database of gene families (Thomas et al. 2003, Mi et 
al. 2013) 
 
 
5.11. Statistical analysis 
 
 
Differences between the control and treatment groups were analyzed with 
unpaired t-tests, and a statistical difference was established when the p value was 
less than 0.05. All statistical analyses were performed with GraphPad Prism v5.0 
software (GraphPad Software, San Diego, CA) 
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RESULTS 
 
 
6.1. Changes in the vaginal opening due to neonatal exposure to 
estradiol. 
 
 
The vaginal opening is one of the parameters that indicate the onset of 
puberty in rats, because there is a physiological increase of ovarian steroids that 
favor vaginal development and the beginning of estrous cyclicity (Ojeda & Skinner 
2006). Figure 6  shows the age of vaginal opening development in the controls 
and EV-treated rats. Figure 6A shows the onset of the vaginal opening for each 
animal from the study groups and the age when 50% of the animals achieved the 
vaginal opening. All of the EV-exposed rats achieved vaginal opening earlier than 
the rats in the control group, some of them as early as 27-days postnatally. Figure 
6B shows the average age when the animals achieved the vaginal opening (30.4 
± 2.6 days in the EV-treated rats versus 33.8 ± 1.6 days in the control rats; p < 
0.001). 
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Figure 6. Estradiol valerate treatment induces early vaginal opening in rats.  
A. Age at time of vaginal opening. Data are shown as a percentage of the rats with 
opened vaginas by age (n = 22 for estradiol valerate; n = 26 for controls); squares indicate 
the age at which 50% of the rats achieved vaginal opening ± SD. B. Average age at which 
the vaginal opening occurred in each group; data are shown as the mean age at the time 
of vaginal opening ± SEM. ***p < 0.001. 
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6.2. Measurements of estradiol serum levels. 
 
Our laboratory has shown that neonatal exposure disrupts normal ovarian 
morphology and that this effect is permanent, it being possible to observe months 
after the EV administration (Cruz et al. 2012). To determine how long the EV 
remains in circulation, we measured the estradiol serum levels in the control and 
EV-treated rats from the time they were 2-day old until they were 60-days old 
(Figure 7). We found a 13.5-fold increase in E2 (estradiol) 24 hours after exposure 
to the EV (1792 ± 178.6 pg/mL versus 132.6 ± 17.08 pg/mL for the controls; p < 
0.001). There were no differences between the controls and treated groups of 15-
, 30-, or 60-day old rats (Figure 7). Previous studies in our laboratory have 
determined that the EV half-life is 1.8 days in neonatal rats (Tiszavari 2013); thus, 
based on 5 times the half-life, the injected EV would persist in circulation for 10 
days, providing strong support to substantiate the hypothesis that the effects of 
estradiol occur early in life and last throughout the reproductive life of the rat. 
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Figure 7. Serum levels of estradiol in rats treated with estradiol valerate 
(EV). 
Data are shown as pg/mL ± SEM. For 2-day old rats, n = 4 for controls and n= 5 
for EV-treated rats; for 2.5-day old rats, n = 4 for controls and n = 6 for EV-treated rats; 
for 3.5-day old rats, n = 4 for controls and n = 5 for EV-treated rats; for 4.5-day old rats, 
n = 5 for both the controls and EV treated rats; for 15-day old rats, n = 5 for controls and 
n = 7 for EV-treated rats; for 30- and 60-day old rats, n = 6 for both the controls and EV 
treated rats. ap < 0.001 vs control; bp < 0.001 vs previous age in the same group. There 
were no differences between the controls. Data for the 2.5- to 4.5-day old rats were taken 
from Michelle Tiszavari’s Master thesis in Biochemistry(2013)..  
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6.3. Effects of EV on the expression of nuclear receptors in the ovary. 
 
 
 Estradiol acts through its receptor and can modulate the expression of 
other nuclear receptors and/or coregulators. Some studies have also shown 
permanent changes in the reproductive function or ovarian morphology when a 
newborn rodent is exposed to estradiol or estrogenic compounds (Sotomayor-
Zarate et al. 2008, Zama & Uzumcu 2009, Rodriguez et al. 2010, Sotomayor-
Zarate et al. 2011, Cruz et al. 2012).  Using a PCR array that allowed 84 genes 
to be analyzed simultaneously, this part of the study was focused on determining 
the short-term effect of EV-exposure in neonatal rat ovaries (2-day old) on genes 
related to the signal transduction pathway or gene targets of estradiol, thus 
providing preliminary evidence of an altered pathway. All of the results comparing 
the expression of the control and EV-treated rats are shown in the Appendix 
(Table 5). Figure 8A shows a scatter plot of the fold change in gene expression of 
EV-exposed rats in comparison to the controls. The cut-off for up- or 
downregulation was set at a minimum of a 2-fold change in comparison to the 
control values. The results are shown as the Fold-Change [2^(- Delta Delta Ct)] 
as described in the Methods section. Five of the analyzed genes showed 
differential expression in the EV-exposed rat ovaries (Figure 8B) the androgen 
receptor (AR, overexpressed 2.12-fold), estradiol receptors alpha and beta (Esr1, 
Esr2, downregulated 2.11- and 2.64-fold, respectively), estrogen-related receptor 
gamma (Esrrg, downregulated 2.2-fold), and nuclear receptor coactivator 3 
(Ncoa3, overexpressed 3.06-fold). Interestingly, the altered genes are related to 
the action and regulation of estradiol and androgen in reproductive tissues (Weil 
et al. 1998, Pelletier et al. 2000, Gibson & Saunders 2012, Percharde et al. 2012).   
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Figure 8. Neonatal estradiol valerate exposure induces changes in the gene 
expression of nuclear receptors and coregulators in neonatal ovaries. 
PCR array analysis of mRNA from 2-day old rats exposed to estradiol valerate (EV). A. 
Scatter plot showing the fold change of gene expression in EV-exposed rats in 
comparison to the controls: Black circle, unaltered expression; red circle, upregulated 
gene; green circle, downregulated gene. B. Summary table of the upregulated (positive 
values) and downregulated (negative values) genes that changed by at least 2-fold 
relative to the controls. AR, androgen receptor; Esr1, estradiol receptor alpha; Esr2, 
estradiol receptor beta; Esrrg, estrogen-related receptor gamma; Ncoa3, nuclear 
receptor coactivator 3. 
.  
Gene EV/Control 
AR 2.12 
Esr1 -2.11 
Esr2 -2.64 
Esrrg -2.2 
Ncoa3 3.06 
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Because the PCR array analysis conducted is an overview of the 
expression profile in neonatal ovaries, real-time PCR was performed to validate 
the results using individual ovarian samples. We designed specific primers for that 
purpose for the Ar, Esr1, Esr2, Esrrg, and Ncoa3 genes (see Methods, Table 1 
for details). Figure 9 shows the real time PCR results for the Ar, Esr1, Esr2, Esrrg, 
and Ncoa3 genes using individual samples from 2-day old rat ovaries rather than 
a pool of cDNA. This procedure confirmed that the ovaries from the EV-treated 
rats had higher expression levels of Ar in comparison to the controls (2.19-fold; 
0.47 ± 0.14 versus 0.22 ± 0.06 for the controls; p < 0.05), but there were no 
significant differences in the expression of the other four genes. 
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Figure 9. Real-time PCR quantification of select genes from the PCR array 
analysis of the ovaries from 2-day old rats. 
Genes that were up- or downregulated 2-fold relative to the controls in the PCR array 
were selected for the analysis. Data are shown as the mean ± SEM; *p < 0.05; n = 3 for 
the estradiol valerate-treated rats and controls; each sample was composed of 2 ovaries 
from different animals, i.e., 6 ovaries were analyzed per group. Ar, androgen receptor; 
Esr1, estrogen receptor alpha; Esr2, estrogen receptor beta; Esrrg, estrogen-related 
receptor gamma; Ncoa3, nuclear receptor coactivator 3.  
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6.3.1. Effect of neonatal EV-exposure on androgen receptor expression 
during development. 
 
 
In addition to the neonatal group analyzed previously, real-time PCR was 
performed on peripubertal and adult rat ovaries (30- and 60-day old rats, 
respectively) to analyze the Ar-expression pattern during development and 
determine if neonatal estradiol exposure can alter the Ar expression. These ages 
were used because they represent different stages of reproductive development 
in rats, and hence, different stages of follicular development. There were no 
differences in Ar expression between the control and treated 30-day old rats. In 
contrast, the EV-treated rats that were 60-days old had 6.4-fold less Ar mRNA 
than did the control rats (0.068 ± 0.013 for EV-treated rats versus 0.45 ± 0.163 for 
control rats; Figure 10).  
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Figure 10. Neonatal estradiol exposure induces an alteration in the ovarian 
androgen receptor expression pattern.  
The graph shows the real-time PCR quantification of androgen receptor mRNA levels in 
the ovaries from 2-, 30- and 60-day old estradiol valerate-treated and control rats. Data 
are shown as the mean ± SEM. *p < 0.05; n = 3 for 2-day old rats; n = 6 for 30- and 60-
day old rats. 
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6.3.2. Effect of the neonatal EV-exposure on androgen receptor distribution 
in the ovary. 
 
To analyze the protein levels of AR in the ovaries and determine if the 
neonatal EV-exposure induced changes in its expression, a western blot (WB) 
analysis was performed using the protein extractions from the 60-day old EV-
treated and control rats, because there were major differences in the mRNA levels 
at this age and the main morphological changes are evident in this model. 
Although the expression of AR was high in 2-day old rat ovaries, this group was 
discarded for the WB analysis due to the small size and amount of protein 
obtainable from this tissue. Figure 11 shows the semiquantification of the WB for 
AR from the 60-day old rat ovaries, in which there were no significant differences 
in the protein levels between the EV-treated rats and controls. AR expression is 
heterogeneous in the ovary, expressed in the granulosa, theca, and stromal cells; 
in addition, AR expression depends on the developmental stage of the subject 
and the follicle type (Weil et al. 1998, Galas et al. 2012). Thus, we performed 
semiquantitative IHC for AR to distinguish between the different compartments 
(oocytes and interstitial compartment in 2-day old rats) or follicle types (in 60-day 
old rat ovaries) in which AR is expressed. This enabled us to determine if an effect 
of the EV-exposure was to alter the localization or distribution of AR in the ovary. 
Figure 12 shows the IHC results for the 2-day old rat ovaries. The AR is expressed 
in the cytoplasm of the oocytes, and with a weaker intensity, in the interstitial 
tissue. Based on the immunoreactivity quantification, there were no differences in 
the immunostaining of AR between the EV-treated and control rats in the oocytes 
or interstice. In the 60-day old rats, AR was expressed in the theca and granulosa 
cells, the oocyte, and interstice. There was more immunoreactivity in the antral 
follicles and interstitial tissue from the EV-treated rats than in the control rats, but 
there were no differences in the preantral follicles between two groups. In addition, 
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the AR immunoreactivity signal was stronger in the antral follicles than that in the 
preantral follicles in the EV-treated rats (Figure 13G).  
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Figure 11. Western blot analysis of androgen receptor protein levels in the 
ovaries from 60-day old rats. 
Data are shown as the optical density quantified from each band normalized against the 
optical density obtained from β-tubulin bands used as a loading control. The bottom panel 
shows a representative image of the Western blot. n = 6 for each group. AR, androgen 
receptor; EV, estradiol valerate-treated rats. No significant differences were found 
between the groups. 
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Figure 12. Androgen receptor is present in the ovary beginning in the 
neonatal period. 
A–F. Immunohistochemical detection of androgen receptor (AR) in the ovaries of 2-day 
old rats: A–C, representative images from control rats; D–F, representative images from 
an estradiol valerate-treated rat. C and F are negative controls, i.e., without the primary 
antibody. Images in A and D, 100× magnification; images in B, C, E, and F, 400× 
magnification. Arrow heads indicate oocytes. G. Semiquantification of AR, expressed as 
a relative percentage. The total integrated optical density (IOD) of the whole ovary slice 
in the image was considered 100%, against which the contribution of each oocyte was 
calculated. Each group was composed of 3 animals with 4 slices per ovary. Data are 
shown as the mean ± SEM. ***p < 0.0001.  
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Figure 13. Androgen receptor immunohistochemistry in the ovaries of 60-
day old rats  
A-F. Immunohistochemical detection of androgen receptor (AR): A–C, representative 
images from control rats; D–F representative images from an estradiol valerate-treated 
rat. C and F are negative controls, i.e., without the primary antibody. Images in A, C, D, 
and F, 100× magnification; images in B and E, 400× magnification. Arrow head, 
secondary follicle; arrow, oocyte; asterisk, type 3 follicle. G. Semiquantification of AR, 
expressed as a relative percentage. The total integrated optical density (IOD) of the whole 
ovary slice in the image was considered 100%, against which the contribution of each 
oocyte was calculated. H. Normalized IOD per number of follicles. Each group was 
composed of 3 animals with 4 slices per ovary. Data are shown as the mean ± SEM. *p 
< 0.01; **p < 0.001; ND = not detected..  
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6.3.3. Effect of neonatal EV-exposure on the methylation pattern of the 
androgen receptor gene. 
 
 
The exposure to EDs during early development has been related to 
folliculogenesis failure, infertility, and polycystic ovaries due to DNA methylation 
and/or histone deacetylation associated with genes that control folliculogenesis 
or the response to hormones (Uzumcu et al. 2006, Zama & Uzumcu 2010). ). 
Since the expression pattern of AR changed as a result of a single dose of EV 
during the neonatal period, and was maintained without further exposure to EV, 
we proposed that these alterations were due to epigenetic programming of the 
AR expression. To determine this, we analyzed the global methylation pattern to 
identify differentially methylated regions in 60-day old rat samples where the 
morphologic and functional alterations induced by the EV are evident by changes 
such as the appearance of follicular cysts, absence of corpora lutea, infertility, and 
increased ovarian noradrenaline concentration (Sotomayor-Zarate et al. 2008).  
We performed an MCIp and genome-wide DNA methylation mapping assay and 
distinguished between the GCs and RO to avoid cross information coming from 
the different cell types. Although the analysis of this assay focused on Ar, we also 
obtained information about the whole genome of our samples with regard to the 
DNA and RNA-seq (GCs and ROs from 60-day old rats; data not shown). Figure 
14 shows the methylation enrichment pattern of the Ar sequence from the MCIp 
analysis. The methylation content of the sequence is shown as a peak, where the 
height represents the number of reads from each genomic interval. We compared 
the methylation content between the GCs and RO of 60-day old rats (EV-treated 
and controls). Note that the methylation enrichment was localized in the first exon, 
and no peaks were observed in the remainder of the sequence. There were no 
significant differences between the EV-exposed and control groups in the global 
methylation pattern of the Ar sequence or in the GCs or ROs. 
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Transcriptional control in eukaryotic cells involves several levels of 
regulation. The concentrations and activities of the activators and repressors 
controlling the transcription of numerous protein-coding genes are regulated 
during cellular differentiation and in response to signals and hormones from 
nearby cells. These activators and repressors in turn regulate modifications to the 
chromatin structure and histone acetylation/deacetylation, thus influencing the 
binding of general transcriptions factors to promoters. The activators and 
repressors also directly regulate transcription initiation-complex assembly and the 
rate at which they initiate transcription (Lodish et al. 2000). DNA methylation is 
known to be associated with the inhibition of protein binding to the DNA strand. 
Methylated DNA has reduced biochemical reactivity and enhanced stability, and 
the transcription factors may not bind to the methylated DNA.  
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Figure 14. Methylation profile of the androgen receptor locus in the ovary of 60-day old rats. 
Comparison of DNA methylation maps of the androgen receptor (Ar) sequence obtained through methyl-CpG 
immunoprecipitation. The height of the peaks represents the number of reads in each genomic interval for each track 
normalized to the same genome-wide read count. Ar, androgen receptor; EV, estradiol valerate-treated rat; GC, granulosa 
cell; RO, residual ovary. Each CpG is shown as black lines at the bottom of the image. There was no CpG island in the 
sequence. The image was obtained using the UCSC browser. 
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DNA methylation is known to be associated with the inhibition of protein 
binding to the DNA strand. Methylated DNA has reduced biochemical reactivity 
and enhanced stability, and the transcription factors may not bind to the 
methylated DNA (Chan & Baylin 2012, Lee et al. 2014). 
  
The MassArray analysis was performed to determine if the altered 
expression of AR was related to changes in DNA methylation associated with 
transcription factor binding sites or the promoter region, thereby controlling Ar 
expression. The analysis was performed twice, and both datasets are presented 
for the GCs (Figure 15) and ROs (Figure 16). Data with poor quality spectra (i.e., 
short or no well-defined peaks) are shown in red. For the genomic regions that 
were analyzed, no major differences were found in the methylation pattern of the 
CpGs contained in the sequences associated with STAT3, “ERE1” (an estradiol 
response element located close to the first exon), “ERE2”, “ERE3” (EREs located 
downstream), nuclear factor kB (Nfkb), or the promoter regions (“promoter_1” and 
“promoter_4”) for any age or compartment. However, the NBRE binding site—the 
response element of the nerve growth factor induced-B, Ngfib—from EV-treated 
60-day old rat RO was hypomethylated to ~30% of that in the controls of the same 
age (Figure 16). No significant differences were found in the promoter region for 
any group analyzed. 
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Figure 15. Estradiol valerate treatment induces changes in the methylation pattern of androgen receptor-
associated sequences in granulosa cells. 
The methylation status of the individual CpGs found in the granulosa cell fraction is shown as a heat map. Each CpG is 
represented by a small square with the methylation levels ranging from 0% (white) to 100% (dark blue). Red values are those 
with poor spectra quality. ERE, estrogen response element; ND, not determined. 
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Figure 16. Estradiol valerate treatment induces changes in the methylation pattern of androgen receptor-
associated sequences in residual ovary. 
The methylation status of individual CpGs found in the residual ovary fraction is shown as a heat map. Each CpG is represented 
by a small square with the methylation levels ranging from 0% (white) to 100% (dark blue). Red values are those with poor 
spectra quality. ERE, estrogen response element; ND, not determined. 
 53 
 
6.4. Effects of neonatal EV-exposure on the expression of growth factors. 
 
 
Our laboratory has demonstrated that neonatal exposure to a single dose 
of estradiol valerate induces morphological changes in the ovary that are 
permanent throughout the lifespan of the rat (Sotomayor-Zarate et al. 2008, Cruz 
et al. 2012). Different growth factors are involved in the folliculogenesis and PCO 
morphology (Teixeira Filho et al. 2002, Dumesic et al. 2007). To determine the 
effect of neonatal exposure to estradiol on the expression of growth factors, we 
performed a PCR array analysis using adult ovaries (60-day old rats) in which the 
morphological changes are evident. Figure 17A shows a scatter plot of the fold 
change in gene expression of EV-exposed rats in comparison to the controls. 
Similar to the analysis done for the Ar, at least a 2-fold change in comparison to 
the control values was considered the cut-off for up- or downregulation. The 
complete set of results is shown in Table 6 (Appendix). Based on these criteria, 
25 genes had altered expression as measured by the mRNA levels. Figure 17B 
shows the fold-changes of the genes in the EV-treated rats in comparison to the 
controls. Of these genes, Amh, vascular endothelial growth factor, transforming 
growth factor β (Tgf-β), inhibin beta-B, bone morphogenetic proteins (BMP), 
fibroblast growth factor, and hepatocyte growth factor have previously been found 
to be altered in the PCO (Lambert-Messerlian et al. 1997, Abd El Aal et al. 2005, 
Pellatt et al. 2007, Raja-Khan et al. 2013, Şahin et al. 2013, van Houten et al. 
2013). Members of the TGFβ family such as AMH, TGF-β, and the BMPs play 
important roles in follicle recruitment, follicle selection, and FSH responsiveness 
(van Houten et al. 2013). In this analysis, Ngf, Bmp6, and Bmp7 (among others), 
which are important factors controlling many ovarian functions, including 
ovulation, did not change in response to the EV treatment (Table 6, Appendix). 
Because of the close relationship between AMH and PCOS in humans, we 
selected this hormone to follow with the analysis.   
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A.                                        B.  
 
 
 
Figure 17. Neonatal estradiol valerate exposure induces changes in the 
gene expression of growth factors in the adult ovary. 
PCR array analysis of mRNA from 60-day old rats exposed to estradiol valerate (EV). A. 
Scatter plot showing the fold change in gene expression in the EV-exposed rats relative 
to the controls: black circle, unaltered expression; red circle, upregulated gene; green 
circle, downregulated gene. B. Summary table of the upregulated (positive values) and 
downregulated (negative values) genes that changed by at least 2-fold relative to the 
controls.  
Gene  EV/Control 
Amh 3,7 
Bmp10 -2,97 
Bmp2 2,56 
Bmp4 2,25 
Clcf1 -3,21 
Csf2 2,08 
Ereg -4,23 
Fgf14 3,38 
Fgf17 2,49 
Fgf8 2,69 
Fgf9 -2,19 
Figf -3,25 
Mstn 3,07 
Hgf -2,61 
IL-18 -2,55 
Inhbb -4,8 
Lif -6,11 
Noda1 3,13 
Nrg1 2,2 
Tdgf1 2,02 
Tgfb1 -2,79 
Tgfb2 2,11 
Vegfa -4,18 
Vegfb -5,21 
 55 
 
6.4.1. Effect of neonatal EV exposure over anti-Müllerian hormone 
expression in rat ovaries 
 
 
AMH is a glycoprotein of 140 kDa that belongs to the TGF-β superfamily 
that is expressed in granulosa cells and secreted into the circulatory system from 
the time of birth until menopause (Cate et al. 1986). This hormone has been used 
as a marker of ovarian reserve and predictor of the reproductive lifespan of 
healthy women. In PCOS patients, this hormone is two- to three-fold higher than 
in women with normal ovaries (Fallat et al. 1997), and its concentration appears 
to correlate with the severity of PCOS and the resistance to treatment (Piouka et 
al. 2009, Grynnerup et al. 2012). Given this information, we chose to analyze the 
expression of AMH during development and determine the origin of the alteration 
in expression. 
 
The PCR array analysis that was conducted is an overview of the 
expression profile in the adult rats. To validate the results, real-time PCR was 
performed with individual samples (see Methods and Table 1 for the PCR primers 
and protocol details). Figure 18 shows the real-time PCR analysis for Amh in the 
2-, 30-, and 60-day old rat ovaries. In adult EV-exposed rats (60 days old), the 
Amh mRNA level was 3.96-fold higher than that of the controls (0.99 ± 0.25 versus 
0.25 ± 0.07 for the controls; p < 0.05), similar to the results found with the PCR 
array. In the 30-day old EV-exposed rat ovaries, the Amh mRNA level was 2.18-
fold higher than that in the controls (0.758 ± 0.187 versus 0.347 ± 0.069 for the 
controls; p < 0.05). There was almost no expression of Amh in the ovaries from 
the 2-day old EV-exposed and control rats (Figure 18).  
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Figure 18. Real-time PCR quantification of the anti-Müllerian hormone 
mRNA levels in ovaries from estradiol valerate-treated rats. 
Data are shown as the mean ± SEM. *p< 0.05; n = 3 for 2-day old rats; n = 6 for 30- and 
60-day old rats. 
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6.4.2. Effect of neonatal EV-exposure on the distribution of anti-Müllerian 
hormone in rat follicles. 
 
 
Since the expression of AMH depends on the ovarian follicle type, with the 
highest expression found in the preantral and small antral follicles (Pellatt et al. 
2007) we explored the pattern of expression in 60-day old rat ovaries using IHC 
to determine the effect of EV on the distribution of the AMH protein in ovarian 
follicles.  
 
Figure 19A shows the IHC for AMH in 60-day old rats. Specific 
immunostaining was observed in the GCs from the primary to antral follicles, but 
no immunostaining was seen in the theca cells or interstitial tissue. In comparison 
to the control rats, the EV-treated rats had higher levels of immunostaining. There 
was also more AMH immunoreactivity signal in the antral follicles of the treated 
rats than in the preantral follicles (Figure 19G). When the IOD was normalized 
according to the number of quantified structures, the preantral and antral follicles 
from the EV-treated rats had increased AMH immunostaining relative to the 
controls (Figure 19H).  
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Figure 19. Anti-Müllerian hormone expression is increased in the antral 
follicles from adult estradiol valerate-treated rats. 
A–F. Representative images of the immunohistochemistry for anti-Müllerian hormone 
(AMH) in the ovary from a 60-day old rat: A–C, ovary slices from a control rat; D–F, ovary 
slices from an EV-treated rat. Images in A and D, 10× magnification; images in B, C, E, 
and F, 40× magnification. C and F are negative controls, i.e., without the primary 
antibody. G. Relative percentage of AMH in the ovaries from 60-day old rats. The total 
integrated optical density (IOD) of the whole ovary slice in the image was considered 
100%, against which the contribution of each oocyte was calculated H. Normalized IOD 
per number of follicles. Each group was composed of 3 animals with 4 slices per ovary. 
Data are shown as the mean ± SEM. *p < 0.05. AMH, anti-Müllerian hormone; C, control; 
EV, estradiol valerate; ND, not detected.  
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6.4.3. Effect of neonatal EV-exposure on the methylation pattern of the anti-
Müllerian hormone gene in rat ovaries. 
 
 
The exposure to EDs such as methoxychlor during development has been 
related to failure in folliculogenesis and an increase in AMH expression (Uzumcu 
et al. 2006). Since the expression pattern of AMH changes due to a single dose 
of EV during the neonatal period and is maintained without further exposure, we 
proposed that these alterations are due to epigenetic reprogramming rather than 
a direct effect of the hormone. To determine this, we analyzed the global 
methylation pattern to identify differentially methylated regions of 60-day old rat 
samples. We performed MCIp and genome-wide DNA methylation mapping of the 
GC fraction and focused the analysis of the assay on Amh. However, we also 
have information about the whole genome of our samples with regard to the DNA 
and RNA-seq (GCs and ROs form 60-day old rats; data not shown). 
Figure 20 shows the methylation enrichment pattern of the Amh sequence 
obtained through the MCIp analysis. The methylation content of the sequence is 
shown as a peak, where the height represents the number of reads in each 
genomic interval; we compared the methylation content between the GCs from 
the 60-day old EV-treated and control rats. Although we did not find any significant 
differences, there was a tendency for greater methylation in the CpG island (exon 
5) of the EV-treated GCs relative to the controls. No major differences in the global 
methylation pattern were found in the other exons. 
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Figure 20. Methylation profile of the anti-Müllerian hormone locus in 60-
day old rat granulosa cells. 
Comparison of the DNA methylation maps for the anti-Müllerian hormone sequence. The 
height of the peaks represents the number of reads in each genomic interval for each 
track normalized to the same genome-wide read count. Amh, anti-Müllerian hormone; 
EV, estradiol valerate-treated rat; GC, granulosa cell; RO, residual ovary. 
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As previously mentioned, DNA methylation is known to be associated with 
the inhibition of protein binding to the DNA strand. Biochemical reactivity is 
reduced and stability is enhanced in methylated DNA, and transcription factors 
may not bind (Chan & Baylin 2012, Lee et al. 2014). Thus, we used the MassArray 
technique with ovaries from 2-, 30-, and 60-day old rats to analyze the methylation 
pattern of transcription factor binding sites and the promoter region associated 
with the control of Amh expression. This technique can differentiate the 
methylation status of individual CpGs, in contrast to MCIp, which can only analyze 
CpG-rich regions. We used the whole ovary from 2-day old rats and the GC-
enriched fraction from the 30- and 60-day old rats. The analysis was performed 
twice, and both sets of data are presented in a heat map (Figure 21). The data 
with poor quality spectra (i.e., short or no well-defined peaks) are shown in red. 
Of the genomic regions that were analyzed, when all 3 age groups were 
compared, there was a differentially methylated pattern in the sequences 
associated with an estrogen response element (“ERE3”) and the promoter region; 
no differences were found between the 2-day old control and treated rats or 
between the 30-day old GCs and controls. No major differences were found in the 
methylation pattern of the CpGs in the sequence associated with STAT3, by age 
or compartment. When ERE3 methylation was analyzed to compare the GCs from 
30- and 60-day old rats, the latter had a higher average methylation of the CpGs 
(EV-treated and control groups) than the 30-day old rats. In the 60-day old rats, 
the ERE sequence of the EV-exposed GCs was hypermethylated in comparison 
to the controls (Figure 21 and 22). No significant differences were found in the 
promoter region for any of the groups analyzed (15% of methylation on average). 
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Figure 21. Estradiol valerate treatment induces changes in the methylation pattern of the anti-Müllerian 
hormone-associated sequence in granulosa cells. 
The methylation status of individual CpGs found in the granulosa cell fraction is shown as a heat map. Each CpG is represented 
by a small square with methylation levels ranging from 0% (white) to 100% (dark blue). Red values are those with poor spectra 
quality. ERE, estrogen response element; ND, not determined. 
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Figure 22. Estradiol valerate treatment induces changes in the methylation 
pattern of the estrogen response element and promoter region of the anti-
Müllerian hormone gene in granulosa cells. 
(Superior Panel) Schematic map of the rat anti-Müllerian hormone gene (from the UCSC 
browser, http://genome.ucsc.edu/). The analyzed CpGs are shown as lollipops; the 
position of the estrogen response element is shown in red. The methylation status of 
individual CpGs found in the granulosa cell fraction is shown as a heat map. Each CpG 
is represented by a small square with methylation levels ranging from 0% (white) to 100% 
(dark blue) Data represent the mean of two independent experiments. Under each panel 
is depicted the methylation difference between the control and estradiol valerate-treated 
rats, ranging from 0 (no methylation) to 1 (100% methylation). Amh, anti-Müllerian 
hormone; ERE, estrogen response element; ND, not determined. 
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6.5. RNA sequencing results 
 
In the GC-compartment analysis of the ovaries from the 60-day old rats, 
when the EV-treated rats were compared to the controls there were 350 
downregulated genes and 289 upregulated genes. When the RO compartment 
was analyzed, there were 579 downregulated genes and 615 upregulated genes. 
Amh was overexpressed by a factor of 2 in the GCs from the EV-treated rats in 
comparison to the controls [log2-Fold-change (logFC) = 0.965, p = 0.039; FDR 
(false discovery rate) = 0.258]. Regarding Ar, there was a 50% decrease in the 
GCs from the EV-exposed rats in comparison to the controls (logFC = -1.09, p = 
0.02; FDR = 0.171), while there was almost no difference in expression in the RO 
(logFC = -0.09; p = 0.847, FDR = 0.96). A gene ontology analysis grouping the 
genes according to their biological processes is also included (see Figures 27 and 
29, in the Appendix)  
 
 
6.5.1 Motif enrichment found in the granulosa cell fraction. 
 
 
Many groups have demonstrated that the changes induced by an early 
exposure to hormones can alter the expression of genes related to 
folliculogenesis, steroidogenesis, and insulin metabolism. To determine which 
gene(s) were altered due to the early exposure to estradiol, we performed RNA-
seq and analyzed the data using the bioinformatic tool HOMER, which contains a 
novel motif discovery algorithm that was designed for regulatory element analysis 
in genomics applications (DNA only). It is a differential motif discovery algorithm, 
which means that it takes two sets of sequences and tries to identify the regulatory 
elements that are specifically enriched in one set relative to the other (Heinz et al. 
2010). We found an enrichment of the transcription factor binding site motifs for 
the fraction of Nfkb-upregulated genes (present in 6.52% of the upregulated 
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genes; q = 0.000). Nfkb has several target genes, one of which is Amh (Lukas-
Croisier et al. 2003, Rey et al. 2003). ). We found other transcription factor binding 
sites in the upregulated genes sequences, but they were insignificant based on 
the q-value, which is a normalization of the p-value for false discovery-rate 
estimation for multiple test sets, in this case, the number of reads that were 
obtained (Noble 2009). These transcription factor binding sites and their function 
are shown in Figure 23, along with the sequence details. Given the special effect 
of EV on Nfkb and the broad effects that this protein has on ovarian function, this 
data shows that it is not just AMH that is altered, but also others factors that may 
be involved in controlling ovarian function. 
 
The Smad3 motif, which is present in 66.30% of the upregulated genes, is 
related to the signal transduction of the TGF-β members, and its signaling 
pathway is used by oocyte secreted factors such as GDF-9 GDF-9B, and BMP-6 
to promote granulosa and cumulus cell growth, also related to ovarian 
development (Kaivo-oja et al. 2006, Dragovic et al. 2007, Schmierer & Hill 2007, 
Gilchrist & Ritter 2011) ). Nuclear receptor 5A2 and NK3 homeobox 1 are related 
to the androgen receptor, which is also enhanced in both our results and PCOS 
pathology (Catteau-Jonard et al. 2008, Nielsen et al. 2011). 
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Figure 23. Motif usage in the granulosa cell fraction of the downregulated 
and upregulated genes. 
Motifs were assigned to transcription factors or transcription factor families based on their 
similarity with known motif matrices. The percentage of target sequences with the motif 
(in parentheses), p-values, and q-values (hypergeometric) for the overrepresentation of 
each motif are shown. The q-value is a multiple-testing correction. 
 
 
 
  
Upregulated gene Motifs  Downregulated genes motifs 
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6.5.2. Motif enrichment found in the residual ovary fraction 
 
 
When the RO fraction was analyzed, there were transcription factor binding 
site motifs that were contained in the sequences of the upregulated and 
downregulated genes that could be related to the function and regulation of the 
ovary. Analyzing the motifs present in the downregulated genes, we found that 
the Ap-1 (present in 17.38% of the sequences) and Sp1 (present in 33.89% of the 
sequences) motifs are related to the transcriptional regulation of CYP11A1 (also 
called P450scc) (Shih et al. 2011). This is interesting because CYP11A1 
expression is increased in the theca cells of PCO patients (Wickenheisser et al. 
2012), yet we found this motif present in the downregulated fraction. Another 
interesting result for future study was that for the RUNX2 motif, which was present 
in 18.2% of the sequences. It has been reported that RUNX2 represses 
preovulatory genes such as prostaglandin-endoperoxide synthase 2, tumor 
necrosis factor alpha induced protein 6, and runt-related transcription factor 1, 
thus allowing the ovulatory process (Park et al. 2012). Others such as the TATA 
box binding protein and the proto-oncogene Jun/AP1 are part of the general 
transcription machinery (Figure 24).  
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Figure 24. Motif usage in the residual ovary fraction of the downregulated 
and upregulated genes. 
Motifs were assigned to transcription factors or transcription factor families based on their 
similarity with known motif matrices. The percentage of target sequences with the motif 
(in parentheses), p-values, and q-values (hypergeometric) for the overrepresentation of 
each motif are shown. The q-value is a multiple-testing correction.  
Upregulated gene Motifs  Downregulated genes motifs 
 69 
 
DISCUSSION 
 
 
A form of PCO resembling some aspects of human PCOS can be induced 
in rats by a single injection of estradiol valerate. This model has been widely used 
for studying PCO and the metabolic effects of hormone expression that resemble 
human PCOS such as oligo/anovulation, follicular cysts, and insulin resistance 
(Schulster et al. 1984, Brawer et al. 1986, Grosser et al. 1987, Carriere et al. 1988, 
Lara et al. 2000, Rosa-e-Silva et al. 2003, Sotomayor-Zarate et al. 2008, 
Alexanderson et al. 2009, Sotomayor-Zarate et al. 2011, Cruz et al. 2012, 
Figueroa et al. 2012, Padmanabhan & Veiga-Lopez 2013). Although the steroid-
induced PCO model in rats lacks some characteristics of women with PCOS, such 
as high androgen plasma levels, the ovary presents a high androgen secretory 
and biosynthetic capacity (Barria et al. 1993, Rosa-e-Silva et al. 2003). Brawer et 
al. (Schulster et al. 1984, Brawer et al. 1986)  demonstrated that administering 
estradiol to adult rats induces the polycystic condition 60 days after the hormone 
exposure. Later, Rosa-e-Silva et al. (2003) and Sotomayor-Zárate et al. (2008) 
verified that the same occurred in rats that were injected with EV at 14 days of 
age and in the first day after birth, respectively. In addition, our laboratory 
demonstrated that there is a temporal window in which the administration of EV 
induces irreversible damage to folliculogenesis, ovulation, and the reproductive 
physiology, distinguishing the neonatal stage as a vulnerable period (Cruz et al. 
2012).  
 
Folliculogenesis in rats is initiated during the neonatal period, while in 
humans this process occurs during the third trimester of pregnancy. In other 
words, the model of neonatal exposure to estradiol mimics or resembles the effect 
of abnormal estradiol exposure during the gestational period in humans. This is a 
very important observation because, based on clinical trials and animal models, it 
has been postulated that PCOS originates during the gestational period. Our 
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animal model is also useful for determining the effects of estrogenic compounds 
without the influence or participation of maternal hormones that could interfere 
with a proper analysis. The use of estradiol valerate rather than other endocrine 
disruptor chemicals has the advantage of a pure estrogenic effect, unlike other 
animal models that study the effects of EDs such as methoxychlor on the 
reproductive system, which has estrogenic, antiestrogenic, and antiandrogenic 
activities, and bisphenol-A (BPA), which has estrogenic, antiestrogenic, and 
androgenic and thyroid hormone activities (Zama & Uzumcu 2009, Li et al. 2013) 
 
 
7.1. Early effects of neonatal EV exposure. 
 
 
In this study, we found a 13.5-fold increase in plasma estradiol levels 24 
hours after the EV-exposure. In fetuses or newborn rodents, estrogen levels are 
remarkably high, decaying 48 hours after birth (Montano et al. 1995). These levels 
are lower than those observed in the (Montano et al. 1995). These levels are lower 
than the observed in the EV administrated rats 24 hour after exposure, which 
coincide with the beginning of the primordial follicles assembly (Rajah et al. 1992, 
Lei et al. 2010). Several researchers (Kezele & Skinner 2003, Chen et al. 2007, 
Sotomayor-Zarate et al. 2008, Lei et al. 2010, Sotomayor-Zarate et al. 2011) have 
postulated that if estrogen levels remain high, the nest breakdown, follicular 
assembly, expression of transcription factors that regulate oocyte development 
and folliculogenesis, and other growth factors are reduced. Because of the 
absence of sex hormone binding globulin in rats, an alternative control 
mechanism on the estradiol plasma levels exists. Alpha-fetoprotein binds 
estradiol and thus regulates circulating free estradiol, blocking its effects 
(Montano et al. 1995). However, this control mechanism is not able to buffer 
estradiol serum levels higher than those found in fetuses and newborns (Montano 
et al. 1995), such as the concentrations found in this study 24 hours after the EV-
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exposure. The elimination half-life of estradiol allows us to determine that the 
injected estradiol would last ten days in circulation. Thus, the effects seen 
previously and confirmed in this work, such as ovulation failure and follicular cysts 
in adulthood (60-day old rats), are not due to exogenous estradiol remaining in 
circulation, but to effects triggered during the neonatal period. 
 
We also confirmed that the neonatal treatment induced an early onset of 
the vaginal opening. The vaginal opening is one of the parameters that has been 
widely used to correlate with the onset of puberty in rats (Rosa-e-Silva et al. 2003, 
Sotomayor-Zarate et al. 2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012, 
Kinouchi et al. 2012, Borrow et al. 2013, Sangun et al. 2014), because the 
physiological increase of ovarian estradiol derived from follicular development 
favors the development of the vagina and the activation of the reproductive 
hypothalamus to initiate the cycling control of gonadotropins, and hence, ovulation 
(Ojeda & Skinner 2006). It has previously been demonstrated that the precocious 
vaginal opening may be related to an early maturation of the hypothalamus-
pituitary-gonadal axis, possibly due to the estradiol exposure since the same 
phenomena has been seen as a response to higher prepubertal levels of E2 or 
ED-exposure in humans and animal models (Rosa-e-Silva et al. 2003, Rasier et 
al. 2006, Crain et al. 2008).  
 
 
7.2. Effect of EV on the expression of androgen receptor in the ovary  
 
 
Cruz et al. (2012) have shown that female rats exposed to a single dose of 
estradiol during the neonatal period have permanent modifications to their ovarian 
morphology and function, presenting with a polycystic ovary morphology and 
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infertility. The effect of estradiol was also evident at the molecular level beginning 
24 hours after exposure, with increased ovarian mRNA levels of nerve growth 
factor and p75 low-affinity neurotrophic receptor (Sotomayor-Zarate et al. 2008). 
The increase in expression found by Sotomayor-Zarate et al. was statistically 
significant beginning 24 hours after the EV-exposure, just as we found with Ar. 
The increase in the Ar expression might be induced directly by estradiol through 
the ERE found in this gene. Thus, one possible explanation is that the exogenous 
estradiol exerts its detrimental effect on the ovary function through the activation 
or inactivation of different genes (by direct or indirect action of estradiol) related 
to follicular development and folliculogenesis, and hence ovarian morphology. 
 
According to Galas et al. (2012) AR expression is evident from postnatal 
day 1 in the rat and is localized in the cytoplasm of healthy oocytes located inside 
the oocyte nest. Similar results were found in our animal model where AR 
immunostaining was found mainly in the oocyte cytoplasm. It is interesting, but 
not surprising, that the AR mRNA levels were not directly correlated with the 
protein quantification, since the control mechanisms of translation and expression 
differ. The AR gene has EREs in its sequence that can regulate the expression in 
response to estradiol induction, and there is in vitro evidence of the AR induction 
effect of estradiol and BPA (Tang et al. 2004, Richter et al. 2007).  
 
Although the estradiol serum levels in 60-day old rats were comparable 
between the groups, the Ar mRNA levels were drastically diminished (6.4-fold) in 
the EV treated rats. The decreased levels of Ar found in the ovaries from the EV-
treated rats could be due to the decrease in the number of ovarian follicles that 
normally express Ar (Sotomayor-Zarate et al. 2008, Sotomayor-Zarate et al. 
2011). However, the PCR analysis was performed using RNA from whole ovaries, 
and thus it was difficult to interpret the contribution of each follicle type. This bias 
in the technique was overcome by using IHC to determine the localization and 
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hence the pattern of AR expression by follicle type; with this approach we were 
able to determine the contribution of each follicle or ovarian structure to the total 
amount of AR. The AR expression was similar between the preantral and antral 
follicles in the 60-day control rats, but the EV-treated rats showed more AR 
immunostaining in the interstitial tissue and antral follicles than did the controls, 
with the antral follicles more heavily stained than the preantral follicles. This is an 
interesting finding because the number of antral follicles have decreased 60 days 
after EV-exposure (Sotomayor-Zarate et al. 2008, Cruz et al. 2012), meaning the 
increase in AR signal is not due to the number of follicles, but rather to the 
overexpression of AR by the individual follicles. This suggests a failure in the 
control of AR expression in the antral follicles. 
A better approach to the analysis is necessary to examine the expression 
by follicle type and determine the specific follicular expression. Assays such as in 
situ hybridization could be used to compare the RNA hybridization with the IHC in 
the same follicle by using consecutive slices; this technique would also make it 
possible to determine the expression pattern from individual follicles and cell types 
such as the granulosa and theca cells, and the interstice. Post-translational 
modifications in the ARs should also be included in future studies. The AR is 
subject to several post-translational modifications, including the phosphorylation 
of serine and tyrosine residues and the acetylation and sumoylation of lysine 
residues; these modifications regulate the receptor levels and function without the 
requirement for de novo synthesis [reviewed in McEwan et al. (McEwan et al. 
2010, Gioeli & Paschal 2012)]. 
 
Several studies have shown that exposure to EDs during the sensitivity 
window induces epigenetic changes on genes that regulate ovarian function, 
changes which can be observed long after the exposure or even trans-
generationally(Zama & Uzumcu 2009, Zama & Uzumcu 2010, Nilsson et al. 
2012). To determine the possible epigenetic modifications induced by estradiol 
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exposure, we analyzed different transcription factor binding sites associated with 
ARs. We found that NBRE, the response element of nerve growth factor-induced 
B, is hypomethylated in AR DNA from EV-treated RO. NBRE is present in the 
promoter region of many genes, including AR (Dai et al. 2012). ), and has been 
shown to participate in the induction of AR expression in the granulosa cells of 
mice and humans (Li et al. 2010, Dai et al. 2012). NGFI-B, which is expressed in 
theca and granulosa cells, is induced by nerve growth factor (NGF) and luteinizing 
hormone (LH) (Katagiri et al. 2000, Park et al. 2003). Thus, the high expression 
of AR found in the ovaries from the EV-treated rats may be related to the 
hypomethylation of the NBRE sequence of the AR gene, allowing the induction of 
AR by NGFI-B. 
We have previously reported that rats that were exposed to estradiol as 
adults and acquired polycystic ovary morphology had high levels of ovarian NGF 
in comparison to controls; this increase was associated with the ovulation and 
estrous cyclicity failure that is present in the model (Dissen et al. 2000, Lara et al. 
2000). We have also reported that the neonatal exposure to estradiol induced an 
overexpression of Ngf 24 hours after the exposure and that this increase may be 
directly induced by the estradiol, since Ngf has an ERE in its sequence 
(Sotomayor-Zarate et al. 2008). Given this, we postulate that the high levels of 
NGF may induce NGFI-B expression and that this factor then induces Ar 
expression (see Figure 25 for the summary scheme).  
 
However, in the rats exposed neonatally, there was a decrease in ovarian 
NGF when the rats were adults, which may be a consequence of the strong 
reduction in the total follicular population induced by the neonatal estradiol 
administration, and thus, in cells producing the neurotrophic factor (Sotomayor-
Zarate et al. 2008). The use of the GC purification protocol allowed us to obtain 
an enriched granulosa cell fraction of almost 90% purity, based on the results of 
Dr. Mauricio Dorfman’s doctoral thesis (Dorfman 2008) that measured the FSHR 
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mRNA in the GC fraction and RO. He found that there were two orders of 
magnitude difference in the mRNA levels when comparing the GC fraction to the 
RO. However, this protocol cannot separate different follicle types with different 
expression patterns, and hence their methylation profile, or cells that are present 
in the ovary such as fibroblasts or macrophages that can contaminate the 
analysis. The use of cell sorting to separate the GCs and theca cells may be 
useful, but this technique would also be unable to distinguish between GCs that 
are from the preantral or antral follicles. 
 
Some studies have shown a relationship between the increase in AR 
expression in granulosa cells from PCO patients and the increase in circulating 
androgens. The same relationship has been described for the increase in AR 
expression in testosterone-treated adult monkeys from the preantral to the large 
antral follicle stage (Weil et al. 1998, Catteau-Jonard et al. 2008). Hillier et al. 
(1997) have shown that GCs from immature follicles have 4 times as many ARs 
than GCs from pre-ovulatory follicles, suggesting that this decrease is needed for 
ovulation. Therefore, the increase in AR expression found in the antral follicles 
may be related to the ovulation failure reported by our group and others. A 
functional analysis of the influence of hypomethylation on Ar expression is 
needed, and in vitro assays may allow us to determine specifically which CpGs 
and methylation patterns affect AR expression. 
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Figure 25. Scheme of androgen receptor expression regulation in the 
current model. 
Androgen receptor (AR) expression is highest in the granulosa cells of small growing 
follicles, being most abundant in the granulosa cells of healthy preantral to small antral 
follicles and low or absent in the preovulatory follicles of the late follicular stage (Hillier et 
al. 1997). Based on previous findings from our group, the neonatal exposure to estradiol 
may increase the expression of nerve growth factor in the adult ovary, which could induce 
the expression of AR through nerve growth factor-induced B, preventing decay in the 
antral follicles. This increase in AR in the antral or preovulatory follicles may block the 
ovulation process, resulting in the formation of a cyst. 
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7.3. Effect of EV on the expression of anti-Müllerian hormone in the ovary. 
 
 
AMH is expressed in granulosa cells and secreted into the circulatory 
system from the time of birth until menopause (Cate et al. 1986). ). Its serum levels 
seem to correlate with development of the preantral and small antral follicles 
(Hagen et al. 2010), thus making it a marker of ovarian reserve and useful for 
estimating the reproductive lifespan of healthy young women (Grynnerup et al. 
2012). When women with PCOS are compared to women with normal ovaries, 
there have two to three-fold higher serum levels of AMH (Fallat et al. 1997). Some 
studies have shown that infant, young, and adolescent daughters of women with 
PCOS also exhibit higher levels of AMH in comparison to control girls (Sir-
Petermann et al. 2006, Crisosto et al. 2007, Sir-Petermann et al. 2012). In this 
study, we found that the early exposure to a single dose of estradiol not only 
induced increased levels of AMH, but also induced differential methylation in the 
CpGs proximate to the AMH ERE, and the pattern depended on the stage of 
development. We postulate that the methylation in the ERE controls the 
expression of AMH. Estradiol, through its receptors Esr1 and Esr2, can modulate 
AMH expression. Esr2, which predominates in the granulosa cells of growing 
follicles, has an inhibitory effect on AMH expression, while Esr1 has inductive 
activity (Grynberg et al. 2012). The increase in CpG methylation associated with 
the AMH ERE could facilitate the interaction between Esr1 and its response 
element (Grynberg et al. 2012). It is possible that the effect of Esr2 on AMH 
expression is not influenced by methylation in the ERE, because disruption of the 
ERE in human GCs does not alter the inhibitory activity of Esr2 on AMH 
expression. However, this work was with human cells, so it would be necessary 
to perform an analysis with rat sequences. According to the information from 
Qiagen in the manual for the EpiTect ChIP qPCR Primers, the reference 
sequence of the ERE used to analyze the methylation pattern and design the 
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EpiTYPER primers was the ERE from Esr1. Figure 26 shows the proposed 
mechanism. 
 
The high expression levels of AMH found in EV-treated adult rats suggest 
there is a reprogramming of expression in the granulosa cells induced by the 
hyperestrogenic neonatal environment. Although there are no granulosa cells in 
the first days after birth (Rajah et al. 1992, Ungewitter & Yao 2013), the effects of 
estradiol could be exerted in precursor cells, as has been shown in a model of 
prenatal testosterone excess in sheep in which the exposure causes structural 
changes to the mesonephric remnant (Smith et al. 2009), ), which has been 
proposed as a source of granulosa cells [reviewed in Ungewitter and Yao (2013)]. 
However, the proposed mechanism is a simplified view of the possible control of 
AMH through estradiol. Further analyses immunoprecipitating Esr1 or Esr22 
complexed with the ERE sequence in the AMH gene and determining the 
influence of the degree of methylation on the interactions between these factors 
and the expression pattern of AMH are needed to substantiate this hypothesis. 
 
Some studies have shown that the high expression of AMH found in the 
granulosa cells from PCO patients can inhibit the synthesis of FSHR, and thus, 
decrease the response to FSH. During normal follicle development in humans, 
the AMH levels are higher in the small antral follicles with the levels gradually 
decreasing as follicle size increases, and falling exponentially when the follicles 
reach 10 mm, the size at which follicle selection occurs. As the follicle size 
increases and production of AMH declines, the follicles become responsive to 
FSH and selection can occur (Pellatt et al. 2007, Pellatt et al. 2011). The 
overexpression found in our model may be related to a reduced FSH sensitivity 
due to a decrease in FSHR expression and aromatase expression and activity, 
as has been reported in human GCs (Pellatt et al. 2011). This reduction in FSH 
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sensitivity could contribute to the anovulation reported previously (Sotomayor-
Zarate et al. 2008, Sotomayor-Zarate et al. 2011, Cruz et al. 2012). 
 
Based on the genome-wide DNA methylation mapping, exon 5 in Amh is 
hypermethylated in EV-treated GCs in comparison to the controls, although the 
differences were not significant. We were unable to confirm this result using the 
MassArray technique because the CpG island could not be resolved. MassArray 
could help us to do detailed studies of the transcription factor binding sites or 
response elements. We also statistically analyzed the relationship between the 
RNA-seq and the methylation pattern to look for a correlation between methylation 
status and expression. Unfortunately, the RNA-seq data for AMH and AR were 
not useful because the data were not statistically different between the controls 
and treated rats, leading us to discard the study. The lack of statistical difference 
may originate with the high stringency in the RNA-seq analysis, but it may also be 
due to using RNA pools with no biological replicates, even though analyses with 
unreplicated data can be performed and are valid (Auer & Doerge 2010) . The 
lack of significance differences between the controls and treated rats could also 
be due to the nature of the samples used. Granulosa cell AR and AMH expression 
depends on the follicle type, something we were unable to distinguish due to the 
limits of the purification technique. For example, we obtained expression profiles 
for the immune cell molecular markers CD14 and PU. 1 in the granulosa cell 
fraction (data not shown). Further analysis changing some parameters of the 
RNA-seq analysis may be needed. However, the IHC and PCR results supported 
our findings related to the methylation and expression patterns. 
 
Interestingly, we found that some growth factors that are related to ovarian 
function and development were not changed in response to the neonatal 
exposure to estradiol: Ngf, Bmp6, and Bmp7. These data disagree with the 
findings of Sotomayor-Zarate et al. (2008), where 60-day old rats exposed to 
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estradiol during the neonatal period had less NGF in their ovaries than did the 
controls. The results in this thesis correspond to a single assay performed with a 
pool of cDNA, so few conclusions can be made regarding the expression profiles. 
BMP6 is expressed in GCs and regulates FSHR and aromatase mRNA 
expression; BMP7 is produced by theca cells and has been shown to stimulate 
the transition from primordial to primary follicle and induces the proliferation of 
granulosa cells from small antral follicles in vitro (Lee et al. 2001, Visser & 
Themmen 2014). These expression profiles of the Bmps and their expected 
function are not related to what was found in the ovaries from the EV-treated rats, 
where the total follicle number decreased as adults. Taking this information into 
account, we should analyze the expression pattern of these molecules using other 
techniques such as real-time PCR, WB, or IHC, because mRNA levels are not 
always correlated with protein synthesis. 
.   
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Figure 26. Proposed mechanism of anti-Müllerian hormone expression. 
Estradiol induces the granulosa cell expression of anti-Müllerian hormone (AMH) through 
estradiol receptor alpha (Esr1), interacting with the estrogen response element (ERE; 
bottom image) as described by Grynberg et al. (2012). An increase in methylation of the 
CpGs close to the Amh ERE would facilitate the interaction between ESR1 and its 
response element, inducing AMH expression. E2, estradiol; Esr1, estradiol receptor 
alpha. White lollipops indicate unmethylated CpGs; black lollipops indicate methylated 
CpGs; red box indicates the ERE sequence. 
 
 
7.4. Role of AR and anti-Müllerian hormone in PCO. 
 
 
It has been shown that the increase in AMH levels found in PCO patients 
is due to an increase in its synthesis by the granulosa cells (Pellatt et al. 2007), 
and it has been postulated that these high levels contribute to the failure of ovarian 
follicle growth and ovulation reported in both humans and the animal model (Ikeda 
et al. 2002, Pellatt et al. 2011, Grynnerup et al. 2012). The increased AMH could 
reinforce or induce the anovulatory state, inhibiting the growth and selection of 
small preantral and antral follicles, as we have reported occurs from neonatal 
exposure to EV It has also been shown that AMH can inhibit the FSH sensitivity 
of growing follicles by inhibiting FSH-stimulated aromatase expression and 
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activity through the inhibition of promoter II activity and FSH receptor number in 
human granulosa cells, contributing to the follicular arrest and anovulation (Pellatt 
et al. 2011). Our model of early exposure to estradiol resembles and explains one 
of the possible origins of the anovulation found in the current model, focusing on 
AMH and AR reprogramming and the effect of the estradiol exposure during the 
sensitivity window when folliculogenesis is beginning. 
 
Some studies have shown that AR, AMH, and its receptor in granulosa 
cells are overexpressed in women with PCO (Catteau-Jonard et al. 2008). The 
causal relationship between AR and AMH overexpression in PCO is not known; 
in this thesis I am suggesting that there is an epigenetic mechanism that is 
induced by estradiol through its receptor during the neonatal period, because 
AMH and AR may respond to estradiol through the ERE in their sequences 
(Guerrier et al. 1990, Watanabe et al. 2000). A summary of the findings and the 
proposed mechanism is depicted in Figure 27. 
 
We know that the information obtained about the epigenetic modifications 
in GCs or RO has to be complemented with others strategies, since we were 
unable to distinguish between the different types of follicles, which the expression 
pattern of AR and AMH depends on. Information is scarce about epigenetic 
control in rats overall with regard to AMH or AR, making it difficult to make 
statements about the mechanisms of control over the expression of these genes. 
Complementary experiments such as ChIP, a functional analysis of AMH ERE, 
and AR-associated NBRE methylation are needed to evaluate the mechanism of 
programming of the involved genes. 
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Figure 27. Summary scheme of the thesis findings.  
The high levels of estradiol induced by the exposure to estradiol valerate may inhibit or 
delay follicular assembly, inducing less apoptosis and more proliferation of epithelial and 
mesenchymatic cells; this delay would decrease the number of follicles found in 2-day 
old rats (doctoral thesis of Dr. Gonzalo Cruz). The increased levels of estradiol induce a 
reprogramming of the androgen receptor (AR) and anti-Müllerian hormone (AMH) 
expression, by which the antral follicles produce more AMH and AR in 60-day old rats. 
This increase reduces the initial follicular recruitment and follicle stimulating hormone 
sensitivity of the antral follicles, and therefore ovulation. In addition, an increase in the 
AR expression may prevent ovulation. AMH, anti-Müllerian hormone; AR, androgen 
receptor; C, cyst; E2, estradiol; FSH, follicle stimulating hormone; PC, pre-cyst; TIII, type 
3 follicle. 
 
 
 
  
 84 
 
CONCLUSIONS 
 
 
Neonatal exposure to a single dose of estradiol induces overexpression of 
AMH and AR in the adult rat ovary and the early onset of puberty. The proposed 
mechanism involved in the expression pattern is comprised of the following: 
• The methylation of the ERE associated with the AMH gene, inducing AMH 
expression. 
• Hypomethylation of the NBRE sequence associated with the AR gene, 
suggesting AR expression may be induced by NGFI-B in response to Ngf 
and/or LH. 
The methylation pattern found in the AR and AMH genes would explain the 
permanent change in expression in adulthood and the morphological alterations 
of the ovaries found in our model. This epigenetic control over AR and AMH 
expression could explain the inheritance of PCO from mother to daughters. 
 
 
Projections 
 
 
This thesis has opened a new field of research related to the study of the 
molecular mechanisms that are controlling the polycystic ovary morphology in the 
rat model of neonatal estradiol exposure, and hence explores new possibilities in 
the human disease. In that regard, however, the results of this thesis must be 
complemented with in vitro assays to determine the influence of the methylation 
on AR and AMH expression. In addition, the RNA-seq data provided a wealth of 
information regarding the GC and RO transcriptomes from 60-day old rats. This 
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type of information will allow us to perform specific analyses of the transcription 
factors that are altered in this model and to make statements regarding control of 
expression, not just of AR and AMH, but also of Ngf, Bmps, and Gdf9. For 
example, it will be possible to determine if there are different splicing variants of 
the transcripts, in addition to finding new transcripts that are not yet listed in the 
databases. 
 
 Another interesting approach of this research could be an epigenetic profile 
of the celiac ganglion, the hypothalamus, or hypophysis, tissues that are also 
affected by exposure to estradiol as our group has previously reported (Luza et 
al. 1995, Sotomayor-Zarate et al. 2008, Sotomayor-Zarate et al. 2011). This 
analysis would help to establish a more complex outline of the effects of neonatal 
estradiol exposure over the ovary and tissues that control the ovarian function. 
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APPENDIX 
 
10.1. PCR array gene tables 
 
Table 5. PCR array results for nuclear receptors and coregulators from the 
ovaries of 2-day old rats. 
Fold-change [2^(- Delta Delta Ct)] is the normalized gene expression [2^(- Delta Ct)] in 
the test sample divided by the normalized gene expression [2^(- Delta Ct)] in the control 
sample. Fold-regulation represents the fold-change results in a biologically meaningful 
way. A fold-change value greater than one indicates an increase or upregulation, and the 
fold-regulation is equal to the fold-change. A fold-change value less than one indicates a 
decrease or downregulation, and the fold-regulation is the negative inverse of the fold-
change. In comments: A= The gene’s average threshold cycle (Ct) is relatively high (>30) 
in either the control or the test sample, and is reasonably low in the other sample (<30). 
B= The gene’s average Ct is relatively high (>30), meaning that its relative expression 
level is low, in both the control and test samples, and the p-value for the fold-change is 
either unavailable or relatively high (p > 0.05). C= The gene’s average Ct is either 
undetermined or greater than the defined cut-off value (default 35) in both samples, 
meaning that its expression was undetected, making this fold-change result erroneous 
and uninterpretable. Ct, threshold cycle. 
 
Gene  AVG Ct 2^(-Avg.(Delta(Ct)) 
Fold 
Change Fold up or down  
Comments Symbol Control  EV Control  EV (EV/Control)  Regulation 
Ahr 27,07 27,29 0,17 0,16 0,97 -1,03 OKAY 
Ar 23,92 23,01 1,49 3,16 2,12 2,12 OKAY 
Arnt 23,65 23,64 1,80 2,04 1,13 1,13 OKAY 
Brd8 22,7 22,76 3,47 3,75 1,08 1,08 OKAY 
Cops2 21,72 21,92 6,85 6,72 0,98 -1,02 OKAY 
Crebbp 21,72 22,05 6,85 6,14 0,90 -1,12 OKAY 
Med17 24,53 24,61 0,98 1,04 1,07 1,07 OKAY 
Ddx5 19,77 20,05 26,47 24,55 0,93 -1,08 OKAY 
Esr1 22,45 23,7 4,13 1,96 0,47 -2,11 OKAY 
Esr2 26,03 27,6 0,35 0,13 0,38 -2,64 OKAY 
Esrra 29,87 29,83 0,02 0,03 1,16 1,16 OKAY 
Esrrb 35 35 0,00 0,00 1,13 1,13 C 
Esrrg 27,65 28,96 0,11 0,05 0,45 -2,20 OKAY 
Hdac1 22,26 22,17 4,71 5,65 1,20 1,20 OKAY 
Hdac2 21,66 21,6 7,14 8,39 1,17 1,17 OKAY 
Hdac3 23,23 23,28 2,41 2,62 1,09 1,09 OKAY 
Hdac4 23,89 24,18 1,52 1,40 0,92 -1,09 OKAY 
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Table 5. Continuation 
Gene  AVG Ct 2^(-Avg.(Delta(Ct)) 
Fold 
Change Fold up or down  
Comments Symbol Control  EV Control  EV EV/Control  Regulation 
Hdac5 23,2 23,33 2,46 2,53 1,03 1,03 OKAY 
Hdac6 23,32 23,74 2,26 1,90 0,84 -1,19 OKAY 
Hdac7 24,62 24,92 0,92 0,84 0,92 -1,09 OKAY 
Hmga1 27,09 27,16 0,17 0,18 1,07 1,07 OKAY 
Hnf4a 30,79 31,9 0,01 0,01 0,52 -1,92 B 
Kat5 22,77 22,74 3,31 3,81 1,15 1,15 OKAY 
Itgb3bp 24,7 24,49 0,87 1,13 1,30 1,30 OKAY 
LOC679693 24,05 24,27 1,36 1,32 0,97 -1,03 OKAY 
Med1 24,44 24,52 1,04 1,11 1,07 1,07 OKAY 
Med11 23,83 23,69 1,59 1,97 1,24 1,24 OKAY 
Med13 22,42 22,62 4,22 4,14 0,98 -1,02 OKAY 
Med14 23,19 23,07 2,47 3,03 1,22 1,22 OKAY 
Med16 23,19 23,6 2,47 2,10 0,85 -1,18 OKAY 
Med4 24,76 24,95 0,83 0,82 0,99 -1,01 OKAY 
Mta1 22,68 22,82 3,52 3,60 1,02 1,02 OKAY 
Ncoa1 22,71 22,95 3,45 3,29 0,95 -1,05 OKAY 
Ncoa2 22,35 22,76 4,43 3,75 0,85 -1,18 OKAY 
Ncoa3 27,66 26,22 0,11 0,34 3,06 3,06 OKAY 
Ncoa4 21,88 21,72 6,13 7,72 1,26 1,26 OKAY 
Ncoa6 23,54 23,59 1,94 2,11 1,09 1,09 OKAY 
Ncor1 23,39 23,42 2,15 2,37 1,10 1,10 OKAY 
Ncor2 23,27 23,15 2,34 2,86 1,22 1,22 OKAY 
Nfkb2 24,93 24,93 0,74 0,83 1,13 1,13 OKAY 
Nono 19,8 19,9 25,92 27,24 1,05 1,05 OKAY 
Notch2 22,48 22,91 4,04 3,38 0,84 -1,20 OKAY 
Nr0b1 27,12 27,72 0,16 0,12 0,74 -1,35 OKAY 
Nr0b2 28,95 29,5 0,05 0,04 0,77 -1,30 OKAY 
Nr1d1 25,56 25,99 0,48 0,40 0,84 -1,20 OKAY 
Nr1d2 23,5 23,88 1,99 1,73 0,87 -1,16 OKAY 
Nr1h2 35 23,6 0,00 2,10 3044,26 3044,26 A 
Nr1h3 27,13 27,35 0,16 0,16 0,97 -1,03 OKAY 
Nr1h4 31,16 31,41 0,01 0,01 0,95 -1,06 B 
Nr1i2 31,55 31,59 0,01 0,01 1,10 1,10 B 
Nr1i3 28,69 28,66 0,05 0,06 1,15 1,15 OKAY 
Nr2c2 23,96 24,15 1,45 1,43 0,99 -1,01 OKAY 
Nr2f1 23,2 23,39 2,46 2,42 0,99 -1,01 OKAY 
Nr2f2 20,13 35 20,62 0,00 0,00 -26581,32 A 
Nr2f6 23,6 23,84 1,86 1,78 0,95 -1,05 OKAY 
Nr3c1 23,29 23,69 2,31 1,97 0,85 -1,17 OKAY 
Nr3c2 27,73 27,98 0,11 0,10 0,95 -1,06 OKAY 
Nr4a1 26,83 26,35 0,20 0,31 1,57 1,57 OKAY 
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Table 5. Continuation 
Gene  AVG Ct 2^(-Avg.(Delta(Ct)) 
Fold 
Change Fold up or down  
Comments Symbol Control  EV Control  EV EV/Control  Regulation 
Nr5a1 23,88 24,46 1,53 1,16 0,75 -1,33 OKAY 
Nr6a1 26,7 26,83 0,22 0,22 1,03 1,03 OKAY 
Nrip1 23,35 22,75 2,21 3,78 1,71 1,71 OKAY 
Pcaf 24,82 24,96 0,80 0,82 1,02 1,02 OKAY 
Ppara 25,59 25,91 0,47 0,42 0,90 -1,11 OKAY 
Ppard 24,64 24,67 0,91 1,00 1,10 1,10 OKAY 
Pparg 28,21 28,9 0,08 0,05 0,70 -1,43 OKAY 
Ppargc1a 27,49 27,98 0,13 0,10 0,80 -1,25 OKAY 
Ppargc1b 27,11 27,6 0,16 0,13 0,80 -1,25 OKAY 
Nr2c1 24,7 24,78 0,87 0,93 1,07 1,07 OKAY 
Psmc3 21,43 21,19 8,37 11,14 1,33 1,33 OKAY 
Psmc5 23,62 23,46 1,84 2,31 1,26 1,26 OKAY 
Rara 23,61 23,51 1,85 2,23 1,21 1,21 OKAY 
Rarb 25,58 25,63 0,47 0,51 1,09 1,09 OKAY 
Rarg_mapped 23,7 23,63 1,74 2,05 1,18 1,18 OKAY 
Rbpsuh 23,07 23,19 2,69 2,79 1,04 1,04 OKAY 
Rora 25,68 26,13 0,44 0,36 0,82 -1,21 OKAY 
Rxra 23,1 23,54 2,63 2,19 0,83 -1,20 OKAY 
Rxrb 24,18 24,76 1,24 0,94 0,75 -1,33 OKAY 
Rxrg 28,63 29,68 0,06 0,03 0,54 -1,84 OKAY 
Tgs1 25,03 25,39 0,69 0,61 0,88 -1,14 OKAY 
Thra 23,45 23,98 2,06 1,61 0,78 -1,28 OKAY 
Med24 22,79 22,97 3,26 3,24 0,99 -1,01 OKAY 
Thrb 28,72 28,72 0,05 0,06 1,13 1,13 OKAY 
Trip4 25,15 25,25 0,64 0,67 1,05 1,05 OKAY 
Vdr 30,47 30,03 0,02 0,02 1,53 1,53 B 
Rplp1 16,39 16,19 275,53 356,54 1,29 1,29 OKAY 
Hprt1 24,29 24,13 1,15 1,45 1,26 1,26 OKAY 
Rpl13a 18,67 18,93 56,73 53,37 0,94 -1,06 OKAY 
Ldha 21,31 20,48 9,10 18,23 2,00 2,00 OKAY 
Actb 16,96 16,82 185,60 230,39 1,24 1,24 OKAY 
RGDC 35 34,76 0,00 0,00 1,33 1,33 B 
RTC 21,9 22,73 6,05 3,83 0,63 -1,58 OKAY 
RTC 21,89 22,73 6,09 3,83 0,63 -1,59 OKAY 
RTC 21,65 22,03 7,19 6,22 0,87 -1,16 OKAY 
PPC 17,95 18,02 93,44 100,28 1,07 1,07 OKAY 
PPC 17,77 18,06 105,86 97,54 0,92 -1,09 OKAY 
PPC 21,56 18,22 7,65 87,30 11,41 11,41 OKAY 
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Table 6. PCR array results for growth factors from the ovaries of 60-day old 
rats. 
Fold-change [2^(- Delta Delta Ct)] is the normalized gene expression [2^(- Delta Ct)] in 
the test sample divided by the normalized gene expression [2^(- Delta Ct)] in the control 
sample. Fold-regulation represents the fold-change results in a biologically meaningful 
way. A fold-change value greater than one indicates an increase or upregulation, and the 
fold-regulation is equal to the fold-change. A fold-change value less than one indicates a 
decrease or downregulation, and the fold-regulation is the negative inverse of the fold-
change. In comments: A= The gene’s average threshold cycle (Ct) is relatively high (>30) 
in either the control or the test sample, and is reasonably low in the other sample (<30). 
B= The gene’s average Ct is relatively high (>30), meaning that its relative expression 
level is low, in both the control and test samples, and the p-value for the fold-change is 
either unavailable or relatively high (p > 0.05). C= The gene’s average Ct is either 
undetermined or greater than the defined cut-off value (default 35) in both samples, 
meaning that its expression was undetected, making this fold-change result erroneous 
and uninterpretable. Ct, threshold cycle. 
 
Gene AVG Ct 2^(-Avg.(Delta(Ct)) Fold Change Fold up or down Comments 
Symbol Control EV Control EV (EV/Control) Regulation  
Amh 23,3 21,8 23,45 86,79 3,70 3,70 OKAY 
Artn 30,19 29,68 0,20 0,37 1,86 1,86 A 
Bdnf 32,82 33,1 0,03 0,03 1,08 1,08 B 
Bmp1 23,6 24,22 19,05 16,22 0,85 -1,17 OKAY 
Bmp10 33,04 35 0,03 0,01 0,34 -2,97 B 
Bmp2 26,19 25,22 3,16 8,11 2,56 2,56 OKAY 
Bmp3 24,82 25,33 8,18 7,51 0,92 -1,09 OKAY 
Bmp4 28,74 27,96 0,54 1,21 2,25 2,25 OKAY 
Bmp5 32,17 32,12 0,05 0,07 1,35 1,35 B 
Bmp6 25,69 25,37 4,47 7,31 1,63 1,63 OKAY 
Bmp7 27,32 27,84 1,45 1,32 0,91 -1,10 OKAY 
Bmp8a 35 35 0,01 0,01 1,31 1,31 C 
Clcf1 28,97 31,04 0,46 0,14 0,31 -3,21 A 
Csf1 26,32 26,78 2,89 2,75 0,95 -1,05 OKAY 
Csf2 33,41 32,74 0,02 0,04 2,08 2,08 B 
Csf3 32,17 31,64 0,05 0,09 1,89 1,89 B 
Cxcl1 27,88 28,52 0,98 0,82 0,84 -1,19 OKAY 
Cxcl12 22,93 23,71 30,31 23,09 0,76 -1,31 OKAY 
Egf 35 34,95 0,01 0,01 1,35 1,35 B 
Ereg 26,58 29,05 2,41 0,57 0,24 -4,23 OKAY 
Fgf1 28,18 28,65 0,80 0,75 0,94 -1,06 OKAY 
Fgf10 31,01 31,75 0,11 0,09 0,78 -1,28 B 
Fgf11 31,92 32,03 0,06 0,07 1,21 1,21 B 
Fgf13 30,54 30,35 0,16 0,23 1,49 1,49 B 
Fgf14 35 33,63 0,01 0,02 3,38 3,38 B 
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Table 6. Continuation 
Gene  AVG Ct  2^(-Avg.(Delta(Ct))  Fold Change Fold up or down  Comments 
Symbol Control  EV Control  EV (EV/Control)  Regulation   
Fgf15 34,31 33,75 0,01 0,02 1,93 1,93 B 
Fgf17 34,61 33,68 0,01 0,02 2,49 2,49 B 
Fgf18 28,26 28,98 0,75 0,60 0,79 -1,26 OKAY 
Fgf2 32,82 32,34 0,03 0,06 1,82 1,82 B 
Fgf22 27,59 28,06 1,20 1,13 0,94 -1,06 OKAY 
Fgf3 30,76 31,59 0,13 0,10 0,74 -1,36 B 
Fgf4 34,43 34,04 0,01 0,02 1,71 1,71 B 
Fgf5 30,64 30,11 0,14 0,27 1,89 1,89 B 
Fgf6 35 35 0,01 0,01 1,31 1,31 C 
Fgf7 28,36 28,6 0,70 0,78 1,11 1,11 OKAY 
Fgf8 27,24 26,2 1,53 4,11 2,69 2,69 OKAY 
Fgf9 26,56 28,08 2,45 1,12 0,46 -2,19 OKAY 
Figf 26,18 28,27 3,19 0,98 0,31 -3,25 OKAY 
Gdf10 30,86 31,29 0,12 0,12 0,97 -1,03 B 
Gdf11 27,23 27,89 1,54 1,27 0,83 -1,21 OKAY 
Gdf5 31,78 31,88 0,07 0,08 1,22 1,22 B 
Mstn 33,73 32,5 0,02 0,05 3,07 3,07 B 
Gdnf 29,03 29,05 0,44 0,57 1,29 1,29 OKAY 
Hgf 28,19 29,96 0,79 0,30 0,38 -2,61 OKAY 
Igf1 23,77 24,29 16,93 15,45 0,91 -1,10 OKAY 
Igf2 26,71 27 2,21 2,36 1,07 1,07 OKAY 
Il11 31,5 31,66 0,08 0,09 1,17 1,17 B 
Il12a 29,66 29,5 0,29 0,42 1,46 1,46 OKAY 
Il18 24,68 26,42 9,01 3,53 0,39 -2,55 OKAY 
Il1a 32,61 33,36 0,04 0,03 0,78 -1,29 B 
Il1b 28,05 28,86 0,87 0,65 0,75 -1,34 OKAY 
Il2 32,85 33,98 0,03 0,02 0,60 -1,67 B 
Il3 33,72 33,61 0,02 0,02 1,41 1,41 B 
Il4 35 34,82 0,01 0,01 1,48 1,48 B 
Il6 32,81 33,68 0,03 0,02 0,72 -1,40 B 
Il7 30,65 30,68 0,14 0,18 1,28 1,28 B 
Inha 18,73 18,78 557,05 703,97 1,26 1,26 OKAY 
Inhba 22,22 22,82 49,58 42,80 0,86 -1,16 OKAY 
Inhbb 22,06 24,71 55,39 11,55 0,21 -4,80 OKAY 
Kitlg 24,04 25,11 14,04 8,75 0,62 -1,60 OKAY 
Lefty1 35 35 0,01 0,01 1,31 1,31 C 
Lep 31,97 31,81 0,06 0,08 1,46 1,46 B 
Lif 28,64 31,64 0,58 0,09 0,16 -6,11 A 
Mdk 22,48 22,33 41,40 60,10 1,45 1,45 OKAY 
Ngf 28,61 28,46 0,59 0,86 1,45 1,45 OKAY 
Nodal 32,96 31,7 0,03 0,09 3,13 3,13 B 
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Table 6. Continuation 
Gene  AVG Ct 2^(-Avg.(Delta(Ct)) Fold Change Fold up or down  Comments 
Symbol Control  EV Control  EV (EV/Control)  Regulation   
Nrg1 27,62 26,87 1,17 2,58 2,20 2,20 OKAY 
Ntf3 28,35 27,89 0,71 1,27 1,80 1,80 OKAY 
Ntf4 29,29 29,67 0,37 0,37 1,01 1,01 OKAY 
Pdgfa 28,19 28,17 0,79 1,05 1,33 1,33 OKAY 
Pgf 29,69 30,72 0,28 0,18 0,64 -1,56 A 
Rabep1 24 25,16 14,44 8,45 0,59 -1,71 OKAY 
S100a6 20,54 21,76 158,87 89,22 0,56 -1,78 OKAY 
Spp1 22,96 22,96 29,69 38,84 1,31 1,31 OKAY 
Tdgf1 32,35 31,72 0,04 0,09 2,02 2,02 B 
Tff1 33,88 34,09 0,02 0,02 1,13 1,13 B 
Tgfa 25,54 26,86 4,96 2,60 0,52 -1,91 OKAY 
Tgfb1 23,87 25,74 15,80 5,65 0,36 -2,79 OKAY 
Tgfb2 26,91 26,22 1,92 4,05 2,11 2,11 OKAY 
Tgfb3 24,69 25,8 8,95 5,42 0,61 -1,65 OKAY 
Vegfa 23,35 25,8 22,65 5,42 0,24 -4,18 OKAY 
Vegfb 28,27 31,04 0,75 0,14 0,19 -5,21 A 
Vegfc 25,19 25,95 6,33 4,89 0,77 -1,29 OKAY 
Zfp91 24,12 25,37 13,28 7,31 0,55 -1,82 OKAY 
Rplp1 17,04 16,88 1797,36 2627,32 1,46 1,46 OKAY 
Hprt1 21,78 22,67 67,26 47,48 0,71 -1,42 OKAY 
Rpl13a 18,16 18,64 826,96 775,71 0,94 -1,07 OKAY 
Ldha 21,45 23,15 84,55 34,05 0,40 -2,48 OKAY 
Actb 17,08 18,59 1748,21 803,07 0,46 -2,18 OKAY 
RGDC 34,9 34,81 0,01 0,01 1,39 1,39 B 
RTC 23,67 23,9 18,15 20,24 1,12 1,12 OKAY 
RTC 22,94 23,14 30,10 34,28 1,14 1,14 OKAY 
RTC 22,89 22,86 31,16 41,62 1,34 1,34 OKAY 
PPC 18,64 18,54 592,91 831,39 1,40 1,40 OKAY 
PPC 18,68 18,58 576,70 808,65 1,40 1,40 OKAY 
PPC 18,63 18,46 597,03 878,79 1,47 1,47 OKAY 
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10.2. Gene ontology analysis. 
 
 
 
 
 
 
 
 
Figure 28. Gene ontology analysis for granulosa cells transcripts. 
Based on RNA sequencing there were 350 downregulated genes and 289 upregulated 
genes in the granulosa cells of the 60-day old, estradiol valerate-treated rats relative to 
the control rats. The genes were grouped according to their biological processes using 
PANTHER (Protein Analysis Through Evolutionary Relationships). 
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Figure 29. Gene ontology analysis for residual ovary cell transcripts. 
Based on RNA sequencing there were 579 downregulated genes and 615 upregulated 
genes in the residual ovary cells of the 60-day old, estradiol valerate-treated rats relative 
to the control rats. The genes were grouped according to their biological processes using 
PANTHER (Protein Analysis Through Evolutionary Relationships). 
 
 
 
 
 
 
  
